



# Tuberculosis: Experimental Models, Innovations, and Challenges

# 28

Sarbjit Singh Jhamb, Raman Preet Singh, and Prati Pal Singh

## Abstract

Tuberculosis (TB) is among the top ten killer diseases and remains the number one cause of death due to infection. A major bottleneck in TB research remains the availability of suitable animal models to understand the disease pathogenesis and progression, immune responses elicited by the pathogen, new molecule and vaccine testing, development and validation of diagnostics, and genetics of the pathogen about these myriad aspects of the infection. Although a broad range of organisms has been employed in TB research, most of the studies have been performed in mice due to cost-effectiveness, ease of handling, availability of immune reagents, and genetically-modified strains as well as ease of availability of strains with a relatively uniform genetic background. The commonly used mouse strains do not mimic human disease progression characteristics. More relevant models like guinea pig and macaque are not frequently employed due to high costs and/or lack of availability of immune reagents. Several models involving alternate, non-pathogenic mycobacteria have been evaluated in mammals and non-mammalian species like fish, frogs, nematodes, and protists. In vitro models such as macrophage infection and co-culture systems provide insights into drug activity and host cell-mycobacterial interactions. An even more straightforward approach relies on using mycobacterial cultures to evaluate drug sensitivity and drug activity. However, the in vitro models suffer from a

S. S. Jhamb (✉) · P. P. Singh

Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research, Mohali, India

e-mail: [sarbjit@niper.ac.in](mailto:sarbjit@niper.ac.in)

R. P. Singh

Department of Pharmacy, Government Polytechnic College, Bathinda, India

Department of Pharmaceutical Sciences, Government Polytechnic College for Girls, Patiala, India

© The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd. 2023

669

P. P. Singh (ed.), *Recent Advances in Pharmaceutical Innovation and Research*, [https://doi.org/10.1007/978-981-99-2302-1\\_28](https://doi.org/10.1007/978-981-99-2302-1_28)

shortcoming that compounds which require metabolic activation by enzymes, such as prodrugs and drug conjugates, could be falsely rejected as being inactive. This is because the cells/tissues employed for in vitro assays may not express the activating enzymes.

---

### Keywords

Experimental models · In vitro · In vivo · Latent tuberculosis · Tuberculosis

---

## 28.1 Introduction

Tuberculosis (TB) continues to inflict mankind since time immemorial and has assumed even more significance in recent decades. TB is the number one killer in the world due to a bacterial infection. TB is a deadly disease that has killed more people than any other infectious disease. According to the World Health Organization (WHO), nearly 10 million people were infected and 1.5 million died in the year 2018 alone making TB one of the top 10 causes of death globally. Clinically, pulmonary TB caused by *Mycobacterium tuberculosis* is the most prevalent among non-HIV-positive patients, while *M. tuberculosis* and *M. avium* complex infection occurs in HIV-positive patients (Iacobino et al. 2020).


Despite efforts from various resources, the dream of TB elimination remains a distant reality. To accomplish it, sustainable and affordable programs are needed with anti-TB measures. To accomplish this task, three areas, vaccination, diagnosis, and treatment, need to be explored. Advancing these areas requires a deeper knowledge of host-pathogen interactions and better experimental models are needed. Animal models of TB are important tools for the assessment of the efficacy of vaccines and potential drug candidates as well as the identification and validation of disease biomarkers (Cardona and Williams 2017; Zhan et al. 2017; Bucsan et al. 2019; Gong et al. 2020).

Treatment of TB is compounded by the long duration of treatment (6 months to 2 years) and the side effects of anti-TB drugs. Both factors contribute to low patient compliance resulting in the re-emergence of infection after an initial recession as well as the emergence of multidrug-resistant strains. Therefore, the focus of new drug development has been to develop drugs that reduce treatment duration, have lesser side effects, and are active against multidrug-resistant strains. The long treatment duration is considered largely due to the continuous backflow of latent TB bacilli; hence, drugs active against latent TB bacilli are desirable (Defraigne et al. 2018; Cohen et al. 2019). After a lull of over half a century, two new anti-TB drugs were approved—bedaquiline (2012) and delamanid (2013) followed by proteomanid (2019). Additionally, investigational molecules like diarylquinolines, fluoroquinolones, nitroimidazoles, and oxazolidinone are in clinical development with a large proportion being that of oxazolidinone (AZD5847, contezolid/MRX-1, sutezolid, delpazolid). Drug repurposing is yet another approach that has resulted in the identification of linezolid and auranofin as treatments for TB. Pretomanid is a novel compound developed by TB Alliance which has been granted authorization

(Khare et al. 2019). The activity of anti-TB drugs has been shown to depend on the immune status of the host which results in lower drug efficacy in immune-compromised patients. Hence, another approach for treatment has been to stimulate the host immune system for bacterial clearance, either as a standalone therapy or in combination with anti-mycobacterial agents (Ahmad et al. 2010, 2011; Gupta et al. 2012; Zhang et al. 2020). These approaches include immunotherapy with small molecules (Mourik et al. 2017; Bryk et al. 2020; Rao Muvva et al. 2021) or microbes and microbial products (Chaturvedi et al. 1999; Hernandez-Pando et al. 2008; Rodrigues et al. 2015). Drug repurposing of existing drugs is yet another viable alternative for the discovery of immune modulator compounds for TB (Mishra et al. 2018). We have found that low doses of morphine can protect infected mice from TB, the protection being comparable to standard anti-TB drugs (Singh et al. 2008). Bacillus Calmette-Guerin (BCG), the only approved TB vaccine, can prevent childhood TB but is ineffective in adults. Over a dozen vaccine candidates are in various stages of clinical trials but are years away from commercialization (Kaur et al. 2019; Li et al. 2020). Other targets of anti-TB drugs have focused on inducing autophagy in macrophages (Pelaez Coyotl et al. 2020; Rao Muvva et al. 2021), disruption of mycobacterial biofilms (Wang et al. 2019), and use of efflux pump inhibitors to overcome drug resistance (Grossman et al. 2015; Pieterman et al. 2018; Xu et al. 2018).

The mouse has been predominantly used as an experimental model of active and latent TB following intravenous inoculation or inhalation exposure to the mycobacterium. Guinea pig is considered a better model for pulmonary TB but is not frequently used due to the risk of aerosol transmission to persons handling these animals. Monkeys remain the most relevant models as they mimic several aspects of pulmonary and extrapulmonary TB which are not observed in other models. However, their high cost of maintenance, high inter-group variability, and limited availability of immune reagents are major obstacles to their application (Cardona and Williams 2017; Bucsan et al. 2019; Gong et al. 2020).

Despite the health impact of TB, research in TB has remained slow. This sluggish pace can be attributed to two factors: the pathogenicity of the organism and the slow growth rate of the organism. *Mycobacterium tuberculosis* (Mtb) infects macrophages (primarily alveolar macrophages) and adapts to the hostile intracellular milieu due to a variety of defense mechanisms. TB is primarily a disease of the respiratory system and the cycle of TB infection commences with the release of Mtb-carrying aerosols. A dose of 1–10 Mtb dispersed in the air is likely to cause a risk of transmission. Following their entry into the lung, Mtb are phagocytized by alveolar macrophage cells where they may either be completely cleared by the immune reactions or may reside and proliferate in macrophages. Under suitable conditions, Mtb may divide and invade the epithelial cells as well. Experimental studies in TB require biosafety level 3 laboratories, which are costly to develop and maintain making these unaffordable to most microbiology laboratories (Bucsan et al. 2019; Gong et al. 2020). The slow growth of *M. tuberculosis* makes it extremely difficult to perform studies since chances of microbial contamination are increased during the 1–2 months long incubation period required to observe colonies on agar



**Fig. 28.1** Schematic diagram showing the different experimental models used currently in tuberculosis research

plates. In recent years, models using non-pathogenic and/or fast-growing alternates such as *M. smegmatis* (Jhamb and Singh 2009; Singh et al. 2009; Altaf et al. 2010; Costa et al. 2016; Arthur et al. 2019), *M. fortuitum* (Alim et al. 2017), *M. bovis* BCG (Altaf et al. 2010), *M. aurum* (Gupta et al. 2009; Gupta and Bhakta 2012), and *M. marinum* (Lienard and Carlsson 2017) have been developed to circumvent these issues. The models commonly employed in the laboratory are summarized in Fig. 28.1. Additionally, luminescence- and fluorescence-based methods employing genetically-engineered bacteria expressing luciferase (Zhang et al. 2012; Andreu et al. 2013) or fluorescent proteins (Zelmer et al. 2012; MacGilvary et al. 2019), as well as the use of fluorescent dyes (Amin et al. 2009), have hastened the screening process not only in experimental studies (Durkee et al. 2019) but also antimicrobial sensitivity of clinical isolates for drug therapy decisions (Amin et al. 2009; Cui et al. 2013). Additionally, polymerase chain reaction-based methods have also been evaluated as faster alternates compared to traditional methods based on the colony-forming unit (CFU) counts (Pathak et al. 2012; da Silva et al. 2017; de Knecht et al. 2017).

## 28.2 In Vivo Models of TB

### 28.2.1 Mouse Model

The mouse has remained a model of choice to study disseminated and pulmonary TB. Nearly a century ago, murine TB was experimentally induced in mice using bovine strains or BCG (Lewis and Margot 1914; Murphy and Ellis 1914; Grumbach et al. 1967; Collins et al. 1975; Forget et al. 1981), whereas *Mtb* infection models in mice appeared much later (Youmans and Mc 1945; Martin 1946; Mc et al. 1946; Youmans and Williston 1946). Several inbred strains of mice have been investigated resulting in their classification as susceptible (Balb/c, C57BL/6, B10.A, I/St, SWR) and resistant (C3H/HeCr, A/J, DBA/2, A/Sn) (Pierce et al. 1947; Kelley and Collins 1999; Nikonenko et al. 2000; Turner et al. 2003b); nevertheless, contrasting classification of mouse strains (C3H/HeJ as sensitive and C57BL/6 as resistant) has also appeared in the literature (Chackerian et al. 2001) highlighting the importance of *Mtb* strain, inoculum size, and route of administration on susceptibility to infection (Actor et al. 1999; Chackerian and Behar 2003). Apart from the inbred strains, outbred strains such as Swiss (Lynch et al. 1965; Lecoecur et al. 1989) and ICR mice (Shkurupy et al. 2020) have also been used which have not been equivocally classified as being susceptible or resistant. The dissemination model requires intravenous injection of millions of CFUs which results in a significant bacterial load in the lungs, liver, and spleen with a small number of bacilli also detectable in other organs and blood. The treatment with test compounds is typically initiated either on the day of inoculation or 24 h post-inoculation and CFU counts in target organs are determined after 1 month of treatment/inoculation (Singh et al. 2008). This model, although convenient for experimental screening of compounds, does not represent the actual pathology of the disease in humans since pulmonary TB is the major manifestation in humans (Cardona et al. 1999). Alternatively, a low-dose aerosol model has been employed which requires exposure of mice to a relatively lower number of bacteria (typically, 50 CFUs) via the inhalation route. The aerosol droplets, owing to their small size, deliver the bacilli in alveoli. After treatment with test compounds, lung CFU counts are determined after 3 or 4 weeks (Kelly et al. 1996; De Groote et al. 2011). A similar approach relies on intratracheal instillation of about a million CFUs in mice which results in the development of aspirating pneumonia but the pathology does not mimic pulmonary TB (Dormans et al. 2004; Eruslanov et al. 2004). Mouse model of pulmonary *M. tuberculosis* infection exhibits immune responses similar to that observed in humans but the disease characteristics differ significantly. Several pathological hallmarks of TB infection in humans such as caseous necrosis, granulomas, and lung cavitations are not observed in mouse strains (Bucsan et al. 2019). The pathogens traffic intracellularly in murine lungs of commonly used BALB/c and C57BL/6 strains in contrast to observations in DBA/2 and 129/Sv mice. This difference translates into differences in pathological outcomes whereby inflammation ensues in murine models but without development of necrotic lesions (Medina and North 1998; Guirado et al. 2006). On the other hand, the disease is progressive in nature in humans and other

experimental models along with development of necrotic lesions with extracellular bacteria. The susceptibility of mice to infection is also impacted by the strain implying a role of genotype. For example, C57BL/6 mice are resistant compared to BALB/c mice, while C3HeB/FeJ mice exhibit development of necrotic granulomas similar to those observed in humans (Driver et al. 2012; Harper et al. 2012; Lee et al. 2018; Moreira-Teixeira et al. 2020). B6.C3H<sup>ss1</sup> mice exhibit hypoxic lesions (Kramnik 2008), while CBA/J IL-10 knockout mice develop mature fibrotic granulomas (Cyktor et al. 2013; Bucsan et al. 2019). In recent years, humanized mice have been developed which not only mimic human pathology but also enable study of HIV/TB co-infection as well as anti-mycobacterial drug screening in mice (Calderon et al. 2013; Heuts et al. 2013; Nusbaum et al. 2016; Grover et al. 2017; Arrey et al. 2019; Corleis et al. 2019; Gong et al. 2020; Huante et al. 2020). Mouse strains also differ in their response to BCG and consequent protection from TB. Balb/C mice exhibit higher degree of immune response compared to C57BL/6 mice but afforded comparable protection from Mtb infection (Garcia-Pelayo et al. 2015). In another study, the effect of prior BCG vaccination on protection from Mtb aerosol infection has also been compared in susceptible (C3Heb/FeJ) and resistant (C3H/HeOuJ) mouse strains (Henao-Tamayo et al. 2015).

The commonly used mouse strains have been criticized in recent years as an oversimplification of human pathology since the effects of allelic variations on disease pathology as well as treatment and vaccination effects could not be studied. Recently, collaborative cross (CC) and diversity outbred (DO) models have been developed which could be used to study the effects of allelic variations on TB. CC model is a panel of recombinant inbred mouse strains derived from an eight-way cross. Five parental strains included two used in mouse genetics (C57BL/6J and 129S1/SvImJ) and three models of common diseases (A/J, NOD/ShiLtJ, and NZO/HiLtJ), while three founder strains included wild-inbred strains (CAST/EiJ, PWK/PhJ and WSB/EiJ) (Churchill et al. 2004; Noll et al. 2019). CC mice have been shown to be susceptible to Mtb infection (Smith et al. 2016, 2019). The diversity outbred (DO) model was obtained from the same eight strains used to obtain the CC model. However, in contrast to the funnel breeding used in the CC model, the DO model was obtained by extensive inbreeding in these strains resulting in outbred DO strains (Churchill et al. 2012). DO model developed at Jackson Laboratories was obtained by using 160 CC mice as founder strains. Pulmonary infection of DO mice with Mtb resulted in super-susceptible, susceptible, and resistant phenotypes (Niazi et al. 2015; Tavolara et al. 2020). BCG vaccination of DO mice followed by aerosol exposure to Mtb also exhibited different intensities of TB infection (Kurtz et al. 2020).

Models of extrapulmonary TB have also been developed in mice representing brain infection. These models typically employ intravenous injection or intratracheal delivery of Mtb strains in Balb/C mice which disseminate to the brain and other organs (van Well et al. 2007; Be et al. 2008; Hernandez Pando et al. 2010; Gupta et al. 2016; Husain et al. 2017). These studies have revealed that Mtb dissemination to the brain is Mtb strain/genotype-dependent. Another model of TB meningitis relies on the intracerebral injection of Mtb which offers two advantages over other

models of central nervous system (CNS) infection. First, the infection is localized to the brain unlike in other models where the infection is disseminated to other organs. Second, the Mtb strains which do not cause meningitis in other models can cause brain infection; thus, a very broad range of Mtb strains could be evaluated (van Well et al. 2007). The dissemination model has also been employed to model intraocular (Abhishek et al. 2019; Basu et al. 2020) and musculoskeletal TB in mice (Kager et al. 2014). Another model employs NOS<sub>2</sub><sup>-/-</sup> mice where intradermal injection of one thousand CFUs in the ear dermis resulted in hypoxia and granuloma formation in the lungs along with significant bacillary load in the spleen (Reece et al. 2010; Kupz et al. 2016).

Latent TB is yet another challenging area that suffers from a lack of suitable models. A mouse model of latent TB called the Cornell mouse model is the most commonly employed model. The original model required infection of mice with Mtb (by intravenous administration) followed by antimicrobial chemotherapy with two drugs for 12 weeks and a rest period of 90 days to obtain detectable CFUs in organs. Several modifications of this model have appeared in literature which vary in the inoculum size of infection, duration between inoculation of mice and commencement of treatment, dose of anti-TB drugs, duration of treatment, and duration of rest period (Scanga et al. 1999). Another model of latent TB requires low-dose aerosol infection in mice followed by a rest period of up to 3 months (Scanga et al. 1999). More recently, a model based on NOS<sub>2</sub><sup>-/-</sup> mice has also been reported (Kupz et al. 2016). Studies in mice have revealed important insights into the persistence of TB suggesting that the microbe can persist in adipose tissue even after clearance from the lungs (Agarwal et al. 2014, 2016; Ayyappan et al. 2019) which is also corroborated by findings in humans (Neyrolles et al. 2006) and rabbits (Ayyappan et al. 2018). Mesenchymal stem cells have also been identified as a home to dormant Mtb in mice (Das et al. 2013; Beamer et al. 2014; Garhyan et al. 2015; Tornack et al. 2017; Fatima et al. 2020; Jain et al. 2020) as well as in humans (Garhyan et al. 2015; Tornack et al. 2017).

Apart from Mtb, several other species of mycobacteria have been used for infection in mice. These studies aimed at either developing short-term models of human TB to decrease the time required for screening of anti-TB compounds or using non-pathogenic strains/species for adoption in non-BSL3 facilities. *M. smegmatis* has been proposed for the screening of antimycobacterial agents in a mouse model (Jhamb and Singh 2009; Singh et al. 2009). *M. smegmatis* has also been employed to understand molecular mechanisms of Mtb pathogenesis (Sha et al. 2017, 2021; Sun et al. 2017; Yang et al. 2017; Li et al. 2019; Guo et al. 2021) as well as expression of proteins for vaccination purposes (Junqueira-Kipnis et al. 2013; Liu et al. 2015a; Kannan et al. 2020; Safar et al. 2020).

Mouse infection models have also been developed to mimic avian (Fujita et al. 2010; Haug et al. 2013; Andrejak et al. 2015; Cha et al. 2015; Bruffaerts et al. 2017; Dong et al. 2017; Babrak and Bermudez 2018) and bovine TB (Logan et al. 2008; Waters et al. 2014; Garcia-Pelayo et al. 2016; Garcia et al. 2020). Mouse models have also provided insights into the role of co-morbidities such as diabetes (Martens et al. 2007; Alim et al. 2017, 2019, 2020) and co-infections such as malaria (Mueller



et al. 2012, 2014; Blank et al. 2016a, b), influenza (Florido et al. 2013; Redford et al. 2014; Ring et al. 2019), herpes (Miller et al. 2019), HIV (Nusbaum et al. 2016), and helminth infections (Monin et al. 2015; Rafi et al. 2015; McFarlane et al. 2017) on the progression of TB.

## 28.2.2 Guinea Pig Model

Guinea pigs were the preferred model for understanding TB pathogenesis and diagnosis as well as drug and vaccine screening (Negre and Bretey 1945; Steenken Jr. and Wagley 1945; Dessau et al. 1949; Steenken Jr. and Pratt 1949; Soltys and Jennings 1950; Wasz-Hockert and Backman 1954; Lithander 1957; Collymore et al. 2018; Williams et al. 2020). Their use in diagnosis has ceased since the introduction of culture medium and other diagnostic tests (Mitchison et al. 1973; Saxena and Sharma 1982; Martin et al. 1989; Smith et al. 1991). Nevertheless, guinea pigs are the second most employed model after mice for drug and vaccine efficacy studies and in understanding disease pathology (Morton 1916; Goyal 1938; Gharpure 1945; Kerr 1946). Guinea pigs exhibit several characteristic features of human TB pathology as observed in humans such as the development of granulomas, caseous necrosis, and secondary lesions after systemic dissemination (Wilkinson and White 1966; Narayanan et al. 1981; Shakila et al. 1999; McMurray 2003; Turner et al. 2003a; Basaraba et al. 2006; Ordway et al. 2007; Via et al. 2008). Although guinea pigs have been addressed as being highly susceptible to TB infection, high CFU counts need to be administered compared to mice. Guinea pigs also do not show any significant observable signs and symptoms of the disease even weeks after the *Mtb* challenge making this species unsuitable for studies where the death of the animal is a study parameter (Smith et al. 1991; Shakila et al. 1999; Williams et al. 2005). BCG vaccine has been shown to be more protective in guinea pigs compared to mice thereby raising concern that guinea pigs may not be a suitable model to screen vaccines better than BCG (Sugawara et al. 2007; Ly et al. 2008; Cardona and Williams 2017; Gong et al. 2020). Further, the lack of immunological reagents is also an impediment to employing guinea pigs in vaccine screening. Guinea pigs have also been employed to study non-pulmonary TB such as pleuritis (Phalen and McMurray 1993), ocular TB (Rao et al. 2009; Thayil et al. 2011), and central nervous system dissemination (Be et al. 2011) as well as TB in co-morbid conditions (Podell et al. 2014). Although highly virulent strains of *Mtb* such as H37Rv and Erdman strains (Palanisamy et al. 2008; Li et al. 2010) as well as clinical isolates (Shanley et al. 2013; Aiyaz et al. 2014; Pardieu et al. 2015) have been used, experimental models of *M. bovis* and BCG infection have also been reported in guinea pigs (Aygun et al. 2000; Chambers et al. 2001). Guinea pig model of latent TB has also been reported (Kashino et al. 2008; Klinkenberg et al. 2008; Rifat et al. 2009; Sugawara et al. 2009; Patel et al. 2011) and found to be suitable for study of latent TB.



### 28.2.3 Non-human Primates

Non-human primates are known to be susceptible to TB and reports have emerged showing the spontaneous spread of infection in wild and captive animals (Schroeder 1938). These include rhesus macaques (Lindsey and Melby Jr. 1966), stump-tailed macaques (Wolf et al. 1967; Indzhiia et al. 1977), squirrel monkeys (Chrisp et al. 1968; Hessler and Moreland 1968; da Silva et al. 2017), spider monkeys (Rocha et al. 2011), cebus monkeys or capuchins (Leathers and Hamm Jr. 1976; Broncyk and Kalter 1980; Ehlers et al. 2020), owl monkeys (Bone and Soave 1970; Snyder et al. 1970), pig-tailed monkeys (Sedgwick et al. 1970; Lau et al. 1972; Stockinger et al. 2011; Engel et al. 2012), lemur (Knezevic and McNulty 1967), langurs (Plesker et al. 2010), baboons (Heywood et al. 1970; Broncyk and Kalter 1980; Fourie and Odendaal 1983; Martino et al. 2007; Wolf et al. 2016), chimpanzees (Chaparas et al. 1970; Broncyk and Kalter 1980; Coscolla et al. 2013; Wolf et al. 2016), mandrills (Amado et al. 2006), grivet (Broncyk and Kalter 1980), marmosets (Broncyk and Kalter 1980; Via et al. 2013), and several species of New World monkeys (Alfonso et al. 2004; Rosenbaum et al. 2015). Non-human primates genetically resemble humans due to evolutionary proximity and hence, exhibit characteristic hallmarks of human TB. These characteristics include the development of caseous necrosis, granulomas, and dissemination of pulmonary TB to other organs (Via et al. 2008; Mattila et al. 2013, 2017; Pacheco et al. 2013; Dutta et al. 2014b; Marino et al. 2015; Esaulova et al. 2020; Wessler et al. 2020). Apart from the characteristic pulmonary pathology, several non-human primates have also been found to exhibit non-pulmonary manifestations of TB such as hepatic (Stockinger et al. 2011), spinal (Martin et al. 1968; Fox et al. 1974), cerebral (Machotka et al. 1975), cutaneous (Bellinger and Bullock 1988) and ocular (West et al. 1981) as well as infection by other species of mycobacteria, including non-tuberculous mycobacteria (Smith et al. 1973; Renner and Bartholomew 1974; Latt 1975; Sesline et al. 1975; Sapolsky and Else 1987; Brammer et al. 1995; Alfonso et al. 2004; Henrich et al. 2007; Chege et al. 2008; Parsons et al. 2010; Wachtman et al. 2011; Via et al. 2013; Rahim et al. 2017; Min et al. 2018). Further, immunological reagents targeted towards human proteins show reactivity with NHP proteins, and vice versa, due to the high degree of sequence and structural homology. Additionally, co-infection with simian immunodeficiency virus also mimics HIV/TB co-infection (Kuroda et al. 2018) and has been employed to study the effect of antiretroviral therapy on active and latent TB progression (Ganatra et al. 2020; Sterling and Lin 2020). However, the high cost of procurement and maintenance along with stringent ethical protocols restrict the use of NHPs to very few laboratories (Gong et al. 2020). Several species of NHP have been investigated as models for screening of anti-TB compounds as well as vaccines but the major species include cynomolgus macaques (*Macaca fascicularis*) (Marino et al. 2004; Dutta et al. 2014b; Tsujimura et al. 2020; Winchell et al. 2020) and rhesus macaques (*Macaca mulatta*) (Fremming et al. 1957; Pacheco et al. 2013; Rayner et al. 2013; Gong et al. 2020; Sterling and Lin 2020). Significant differences between the two species have been reported with regard to TB susceptibility and response to vaccination. Rhesus macaques have been found to be more susceptible to

the development of active TB but BCG vaccination showed poor protection in this species compared to cynomolgus macaques (Langermans et al. 2001). The higher susceptibility of rhesus macaques to develop active TB, compared to cynomolgus macaques, has been attributed to differences in innate immune responses (Maiello et al. 2018; Dijkman et al. 2019) and monocyte: lymphocyte ratios in the two species (Sibley et al. 2019). Further, mutations in the natural resistance-associated macrophage protein 1 (NRAMP1) gene have been linked to differences in intraspecies susceptibility to TB in rhesus macaques (Deinard et al. 2002). The role of the route of administration on disease pathology has also been demonstrated: a uniform disease was obtained following aerosol exposure, while bronchoscopic instillation resulted in disease localized at the instillation site (Sibley et al. 2016). In contrast to rhesus macaques which develop active TB, cynomolgus macaques have been found to develop latent TB following low-dose pulmonary delivery of *Mtb*. These macaques remain asymptomatic, with no clinical manifestations in chest radiography, but show positive tuberculin tests after at least 6 months of *Mtb* administration (Walsh et al. 1996; Capuano et al. 2003; Lin et al. 2006; Flynn et al. 2015; Gideon et al. 2015; Sharpe et al. 2016). Nevertheless, a model of asymptomatic TB has also been described in rhesus macaques (Gormus et al. 2004; Lin et al. 2009). The macaque model has also been used to study the reactivation of latent TB in SIV-TB co-infection models (Diedrich et al. 2020; Ganatra et al. 2020) as well as identify biochemical and cellular markers in latent TB (Esaulova et al. 2020). More recent studies using PET-CT (Coleman et al. 2014a, b; Lin et al. 2016; Stammes et al. 2021), serial intravascular staining (Potter et al. 2021), in silico/mathematical models (Marino et al. 2016; Marino and Kirschner 2016; Pienaar et al. 2016; Sershen et al. 2016; Evans et al. 2020), omics studies (Mehra et al. 2010; Kunnath-Velayudhan et al. 2012; Luo et al. 2014; Gideon et al. 2016; Javed et al. 2016; Pienaar et al. 2016; Hudock et al. 2017; Martin et al. 2017; Thompson et al. 2018; Duffy et al. 2019; Ault et al. 2020), and other methods have been found to be useful in the study of TB pathogenesis in macaques (Lewinsohn et al. 2006; Lerche et al. 2008; Sharpe et al. 2009; Hudock et al. 2014; Pena and Ho 2016).

### 28.2.4 Other Mammalian Models

Rabbits have been employed in TB for a long time. The severity and nature of the infection have been attributed to the strain of the infecting organism as well as the rabbit strain employed (Dorman et al. 2004; Subbian et al. 2013a; Tsenova et al. 2020). Following aerosol challenge with *M. bovis*, rabbits exhibit several characteristics of human disease such as cavitation and granuloma formation (Via et al. 2008; Subbian et al. 2013b; Gong et al. 2020) as well as extrapulmonary dissemination (Nedeltchev et al. 2009). Notably, most of the rabbit strains are not susceptible to common human virulent strains (Gong et al. 2020); however, these strains could produce pulmonary lesions (Bishai et al. 1999; Manabe et al. 2003). The rabbit model has also been modified to study extrapulmonary TB such as meningitis (Tsenova et al. 2005, 2007; Tucker et al. 2016; O'Brien et al. 2020),

spinal TB (Geng et al. 2015; Liu et al. 2015b) and bladder TB (Liu et al. 2015b). Imaging studies have demonstrated localization of administered drugs in pulmonary necrotic lesions thus providing a pharmacokinetic basis for the comparison of drug activity (Kjellsson et al. 2012; Via et al. 2012; Pienaar et al. 2017; Blanc et al. 2018a, b; Rifat et al. 2018; Tucker et al. 2018; Sarathy et al. 2019). A skin infection model has recently been reported in rabbits to assess the virulence of mycobacterial strains and liquefaction potential (Zhang et al. 2010; Sun et al. 2012). The rabbit model has also been investigated for the study of latent TB but the model has not been extensively studied (Manabe et al. 2008; Kesavan et al. 2009; Subbian et al. 2012, 2013b).

The earliest report on a study of TB in rats is over a century old (Bodkin 1918); however, their use in the assessment of drug effects on the course of TB was studied several years later (Smith et al. 1946a, b; Scheid and Mendheim 1949; Michael Jr. et al. 1950; Cummings et al. 1952; Grumbach 1960). Despite their early applications, rats were not extensively investigated as a model of TB. In recent years, several strains and species of rat have been employed such as Fischer rats (Sugawara et al. 2004a), Lewis rats (Sugawara et al. 2004b), Sprague-Dawley rats (Li et al. 1998), Wistar rats (Gaonkar et al. 2010; Singhal et al. 2011a, b), cotton rats (Daigeler 1952; Elwood et al. 2007; McFarland et al. 2010), vole rats (Jespersen 1974) and others (Sugawara et al. 2004c, 2006; Clarke et al. 2007; Sugawara and Mizuno 2008). Nevertheless, preliminary studies have demonstrated the formation of granulomas and pulmonary lesions in rats (McFarland et al. 2010; Heng et al. 2011). The application of rats in studying the effects of vaccines has been a recent development with preliminary studies indicating their utility in screening vaccines (McFarland et al. 2010; Singhal et al. 2011b; Cardona and Williams 2017; Gong et al. 2020). Rats offer additional advantages compared to mice such as the ability to collect multiple blood samples which makes them an attractive alternative to mice for pharmacokinetic studies (Kumar et al. 2014).

Apart from studying the effect of drugs and vaccines, rats have also been investigated for understanding the role of co-morbidities in TB such as diabetes (Sugawara and Mizuno 2008) and silicosis (Dong et al. 2014). Rats have also been investigated in the diagnosis of TB such as cotton rats (*Sigmodon hispidus hispidus*) (Daigeler 1952). African pouched rats have been studied for the olfactory detection of TB in clinical samples. Pouched rats were found to be more sensitive than smear microscopy in the detection of Mtb (Mahoney et al. 2012; Mgone et al. 2012; Ellis et al. 2017; Mulder et al. 2017; Webb et al. 2020).

Hamsters have also been investigated as a model for the study of human and bovine TB pathology (Steenken Jr. and Wagley 1945; Glover 1946; Dennis and Gaboe 1949; Rozenberg and Pisarenko 1965). Pulmonary infection of hamsters has been shown to exhibit tubercle formation and the pathological outcome was dependent on a diet (Ratcliffe and Palladino 1953; Merrick and Ratcliffe 1957). The cheek pouch has also been used as an inoculation site that exhibits granulomatous lesions (de Arruda and Montenegro 1995). Hamsters have also been used to study the antimycobacterial effects of compounds (Rozenberg and Pisarenko 1965; Gupta and Mathur 1969; Righi et al. 1999; Ugaz et al. 1999; Domingues-Junior et al.

2000; Palermo-Neto et al. 2001) as well as the effect of BCG on TB progression (Viallier and Cayre 1955; Rozenberg and Pisarenko 1965). Hamsters, like guinea pigs, have also been investigated in the diagnosis of TB but are not extensively used (Hussel 1951; Eskuchen 1952; Starck and Viehmann 1955). Minipigs have also been investigated as a model of pulmonary *Mtb* infection which exhibits characteristics of human pulmonary lesions such as granuloma formation (Gil et al. 2010; Ramos et al. 2017).

Several other mammalian models have been developed to model TB in wild animals and cattle (Palmer et al. 2012; Reis et al. 2020). These models typically rely on the induction of *M. bovis* infection in animals such as badgers, boars, deer, and possums (Palmer et al. 2012; Reis et al. 2020). These animals act as reservoirs of TB in the wild and play a key role in the spread of TB in wild animals and domesticated cattle (Fulford et al. 2002; Corner et al. 2003; Green et al. 2008; Fenwick 2012; Donnelly and Nouvellet 2013; Nugent et al. 2015; Sichewo et al. 2020). Experimental models of *M. bovis* infections have been developed in badger (Lesellier et al. 2008; Gormley and Corner 2017; Queiros and Vicente 2018), boar (Naranjo et al. 2006; Ballesteros et al. 2009; Gasso et al. 2016; Lopez et al. 2016), deer (Palmer et al. 1999; Mackintosh et al. 2000; Waters et al. 2003; Stringer et al. 2011) and possum (Dennis and Gaboe 1949; Skinner et al. 2002; Cooke et al. 2003; Nugent et al. 2013a, b; Rouco et al. 2016) which have provided insights into disease pathology progression, transmission as well as effects of vaccination on disease control. A model of aerosol infection has also been described in ferrets as a replacement for the badger model (McCallan et al. 2011). Apart from these reservoirs of infection, models of *M. bovis* infection have also been reported in goats (Schinkothe et al. 2016a, b), buffalo (De Klerk et al. 2006) and cattle (Kao et al. 1997, 2007; Joardar et al. 2002; Palmer et al. 2002; Griffin et al. 2006; Rodgers et al. 2007). Additionally, the *M. caprae* infection model has also been reported in goats (Bezoz et al. 2010; de Val Perez et al. 2011). Cattle have been reported to be resistant to *Mtb* (Whelan et al. 2010) but *M. bovis* infection in cattle has been proposed as an alternate model for human TB for evaluating the effect of drugs and vaccines (Dean et al. 2008; Van Rhijn et al. 2008; Waters et al. 2014).

### 28.2.5 Fish and Other Models

Zebrafish infection with *M. marinum* has been a subject of considerable interest in recent years. *M. marinum* induces granuloma formation in zebrafish which resembles lung granulomas in humans (Prouty et al. 2003; Swaim et al. 2006; Davis and Ramakrishnan 2009; Carvalho et al. 2011; Cheng et al. 2020). The investigation of mechanisms of granuloma formation in zebrafish has provided important insights into the mechanisms operable in humans, including mechanisms operable in presence of co-morbidities (Benard et al. 2016; Kenyon et al. 2017; Bouz and Al Hasawi 2018; Johansen et al. 2018; Luukinen et al. 2018; Harjula et al. 2020; Oehlers et al. 2020; Hosseini et al. 2021). The optically transparent adult zebrafish and embryos allow easy visualization of disease progression while also allowing

studies with large sample sizes due to the low cost of maintenance as well as the ability to conduct studies in BSL2 facilities (Myllymaki et al. 2016; Sommer and Cole 2019; Cheng et al. 2020; Gong et al. 2020; Hogset et al. 2020). The zebrafish model has been employed for the screening of anti-TB compounds and candidate vaccines (Oksanen et al. 2013; Lopez et al. 2018; Risalde et al. 2018; Sommer and Cole 2019; Commandeur et al. 2020; Nie et al. 2020; Saralahti et al. 2020; van Wijk et al. 2020). Genetically engineered zebrafish, expressing drug-metabolizing enzymes, has also been employed for studying the activity of anti-TB prodrugs (Ho et al. 2021). The zebrafish model has also been extended to study ocular (Takaki et al. 2018) and latent TB (Parikka et al. 2012) as well as tuberculous meningitis (van Leeuwen et al. 2014; Chen et al. 2018). In vivo models of *M. marinum* infection have also been described in goldfish (Ruley et al. 2002; Hodgkinson et al. 2012) and medaka (Broussard and Ennis 2007; Broussard et al. 2009) as well as in vitro models employing a carp cell line (El-Etr et al. 2001).

*M. marinum* infection model has also been proposed in frogs which results in granuloma formation (Ramakrishnan and Falkow 1994; Ramakrishnan et al. 1997; Cosma et al. 2006; Rhoo et al. 2019). Frog tadpoles are resistant to infection compared with adults (Rhoo et al. 2019) but tadpoles exhibit immune responses against mycobacteria similar to those observed in mammals (Hyo and Robert 2019). In vitro studies using frog macrophages have demonstrated contrasting roles of cytokines in susceptibility to *M. marinum* infection (Popovic et al. 2019). Additionally, *M. marinum* infection model has also been described in the fruit fly (Dionne et al. 2003; Oh et al. 2013; Pushkaran et al. 2019), silkworm (Yagi et al. 2017, 2021), nematodes (Lopez Hernandez et al. 2015; Galbadage et al. 2016), and protists (Solomon et al. 2003; Andersson et al. 2006; Hagedorn and Soldati 2007; Arafah et al. 2013; Kolonko et al. 2014; Sanchez-Hidalgo et al. 2017; Trofimov et al. 2018). *Galleria mellonella* larvae have also been reported to be susceptible to a wide range of mycobacteria, including Mtb, (Asai et al. 2019b, 2020; Budell et al. 2020) and have been employed for screening antimycobacterial compounds (Entwistle and Coote 2018; Asai et al. 2019a). Models of avian TB have also been described in chick and quail (Chaudhuri et al. 1980; Tell et al. 2003).

---

### 28.3 In Vitro Models

Mycobacteria reside in macrophages and dendritic cells; hence, Mtb-infected macrophages have been frequently used as in vitro models to study drug activity and molecular aspects of pathology (Chingwaru et al. 2016; Keiser and Purdy 2017; Pi et al. 2019). Alveolar macrophages are the primary target for pulmonary TB (Cardona et al. 2003; Cohen et al. 2018) while hepatic and splenic macrophages are targets for systemic infection (Ozeki et al. 2006; Sivangala Thandi et al. 2020). Although primary macrophages obtained from the lungs, liver, and spleen appear to be obvious choices for in vitro studies, their application (particularly, alveolar and hepatic macrophages) is thwarted by low abundance and difficulty in the isolation of pure cell types. Splenic macrophages can be obtained in large quantities but exhibit

much lower phagocytic activity compared to alveolar or hepatic macrophages (Guirado et al. 2013). These problems have resulted in a search for more convenient and representative sources of macrophages. Bone-marrow-derived macrophages have found particular interest in this regard as the precursor cells can be obtained in large amounts and can be differentiated into desired cell types using cytokines or conditioned culture media (Keiser and Purdy 2017). However, the high cost of cytokines could be a limiting factor. Peritoneal macrophages are yet another model which has been frequently employed for decades. The naïve/unelicited macrophages are obtained in relatively lower amounts but their numbers can be increased by eliciting the mice with chemicals. The yield of elicited macrophages is several folds higher compared to unelicited macrophages thereby reducing the number of animals required for experimentation. In recent years, several cell lines of murine alveolar macrophage origin have been developed. The cell lines offer several advantages over primary cells such as a virtually unlimited supply of cells with uniformity in genetic, biochemical, and physiological characteristics. Primary macrophages, as well as cell lines derived from a variety of cell lineages from mice (Chingwaru et al. 2016; Andreu et al. 2017), rat (Weikert et al. 2000; Hino et al. 2005; Markova et al. 2005; Hirota et al. 2010) and other animals, have been investigated as *in vitro* models for the study of Mtb-cell interactions (El-Etr et al. 2001; Hino et al. 2005; Keiser and Purdy 2017).

Human alveolar, hepatic and splenic macrophages are difficult to obtain due to ethical reasons; however, in recent years, these have become commercially available but their cost remains a major stumbling block (Henao et al. 2007). Human peripheral blood mononuclear cells (PBMCs) are relatively much easier to obtain, technically as well as ethically, and have also been widely used. These cells are differentiated into macrophages using cytokines or human serum and can then be used for infection with mycobacteria (Duque et al. 2014; Zhang et al. 2018). Several cell lines of human origin have also been used—the THP-1 monocytic cell line is the most frequently used. This cell line can be differentiated into macrophages by treatment with phorbol myristate acetate and then used for Mtb infection (Bai et al. 2010; Mendoza-Coronel and Castanon-Arreola 2016).

Under physiological conditions, macrophages phagocytose the mycobacteria while cytokines released by macrophages and T-cells contribute to macrophage activation and subsequent killing of the intracellular bacteria. The macrophage infection model is considered relevant for *in vitro* screening of anti-TB activity of test compounds since the ability of the test compound to cross biological membranes (plasma and phagosomal membranes of host and mycobacterial cell membrane) and exert activity in a biological relevant milieu can be determined (Clemens et al. 2019). However, this model is an oversimplification of the immune response and macrophage-T-cell co-cultures have been used to decipher the molecular basis of crosstalk between these cell types (Skinner et al. 1997; Lyadova et al. 1998; Gautam et al. 2018). As an alternative, Mtb has been incubated in whole blood to determine immune responses as well as study drug effects (Al-Attayah et al. 2006; Newton et al. 2011; Raposo-Garcia et al. 2017; Cross et al. 2019; Kwan et al. 2020).

Three-dimensional culture and organoids have attracted immense interest in recent years since these methods are more closely related to *in vivo* conditions and have been successfully employed for drug and vaccine screening. A 3D model employing human PBMCs in an extracellular matrix has been shown to mimic human granulomas and found relevant as a model of latent TB (Crouser et al. 2017). Similar 3D models have been employed which either contain a single cell type or co-culture of macrophages with other cell types to mimic lung tissue or granuloma (Braian et al. 2015; Benmerzoug and Quesniaux 2017; Tezera et al. 2017a, b; Palucci et al. 2019; Thacker et al. 2020; Walter et al. 2020). Additionally, precision-cut lung slices and other models have also been reported to study disease pathology and drug effects (Carranza-Rosales et al. 2017; Carius et al. 2020). The hollow fiber system was developed over a decade ago and approved by European Medicines Agency to study as an *in vitro* model for pharmacokinetic/pharmacodynamic studies (Cavaleri and Manolis 2015). This method has been successfully employed for pharmacokinetic/pharmacodynamic studies involving single-drug or multi-drug regimens (Gumbo et al. 2015a, b; Pasipanodya et al. 2015; Srivastava et al. 2016; Klopogge et al. 2019; Pieterman et al. 2021) including the ability to extend the results to children (Srivastava et al. 2020). Additionally, microfluidic systems have also been developed to study environmental milieu and signaling in granulomas as well as a study of drug resistance (Bielecka et al. 2017; Berry et al. 2020).

---

## 28.4 Mycobacterial Cultures

The field of mycobacterial culture has witnessed a steady improvement in terms of the development of culture media and detection methods. These methods are useful in detecting direct-acting anti-TB compounds but are irrelevant for indirect-acting compounds (such as immunomodulators) or those requiring metabolic activation (such as prodrugs) as well as vaccines.

In the case of compounds that act both directly and indirectly, the anti-TB activity determined by these methods is expected to be much lower compared to that observed under *in vivo* conditions. Currently, Middlebrook 7H9 broth is the liquid medium of choice while Middlebrook 7H10 medium and Middlebrook 7H11 medium are commonly employed solid media for experimental purposes. On the other hand, the Lowenstein-Jensen medium is the preferred solid medium for isolating *Mtb* from clinical samples. *Mtb* is a slow-growing bacterium with a doubling time of approximately 20 h which requires 1–2 months of incubation for CFU determination. Therefore, broth media are commonly employed to study the anti-TB activity of test compounds whereby mycobacterial growth is determined using turbidimetry or optical absorbance (Franzblau et al. 2012; Parish 2020). These methods, although widely used traditionally, suffer from low reliability in quantifying live bacteria due to possible interference by cell debris and have hence been superseded by dye-based methods. Colorimetric dyes such as Alamar blue or MTT are converted to fluorescent or colored products by viable bacteria. The



metabolic conversion of dye, and resulting fluorescence/color intensity, is proportional to the number of viable bacteria (Amin et al. 2009; Cui et al. 2013). This provides the advantage that these methods could be adopted to high throughput formats, requires extremely small amounts of test compounds, and decreases operator exposure to pathogenic strains due to automation.

Commercially available radiometric systems such as BACTEC were employed which provided results relatively faster but have been replaced with fluorescence detection systems like MGIT in recent years due to concerns arising out of the use of radioactive media components (Franzblau et al. 2012; Jhamb et al. 2014). Additionally, luminescent methods based on the assay of ATP or luciferase-expressing Mtb have also been employed (Idh et al. 2017; Parish 2020).

A total of 80 amide derivatives had been tested for their anti-TB activity against metabolically active *M. tuberculosis* H37Rv. Out of this 34 compounds were found active at 6.25 µg/mL concentration and 11 of them were further tested for MIC determination. MIC values of these compounds ranged between  $\leq 0.39$  µg/mL and 6.25 µg/mL (unpublished data). Daily percent growth inhibitions values of all the compounds were evaluated in comparison to standard anti-TB drugs INH and rifampin. Further, 19 more compounds for MIC determination against *Mycobacterium tuberculosis* H37Rv were tested. All of these were tested at five different concentrations (0.39, 0.78, 1.56, 3.125, and 6.25 µg/mL) for MIC determination. Out of these, six compounds showed MIC values of  $\leq 0.39$  µg/mL (unpublished data). The rest of the compounds exhibited MIC values between 0.39 and 6.25 µg/mL. Day-wise percent growth inhibition by compounds was also studied to know the possible mode of action. MGIT 960 TB system was also established in our lab for anti-TB drug susceptibility testing. A total of 15 active compounds were tested at a concentration of 6.25 µg/mL by the MGIT- 960 method (unpublished data). All the 15 compounds were found to be active by MGIT as well as BACTEC 460 methods at a concentration of 6.25 µg/ml and the results correlated well with both the methods. A total of 16 Indian isolates were collected from different institutions in India. The isolates were tested by the BACTEC method against standard anti-TB drugs INH, rifampin, streptomycin, and ethambutol at critical drug concentrations of 0.1, 2.0, 2.0, and 2.5 µg/mL, respectively. All the isolates were sensitive to rifampin whereas some isolates were resistant to INH which is one of the two critical first-line anti-TB drugs. A total of 15 compounds were tested at 6.25 µg/mL concentration against one of the isolates which were resistant to INH. Interestingly three compounds were found to be inactive against this isolate whereas 12 compounds were active against this isolate which was resistant to INH. Intra-macrophage anti-TB activity determination against *M. tuberculosis* (in mouse non-activated peritoneal macrophages) was also established and MIC of standard anti-TB drugs was determined using this assay (our unpublished data).

In vitro mycobacterial cultures have also been investigated for the study of latent TB phenotypes. These models aim at mimicking the conditions observed in granulomas such as hypoxia (Aly et al. 2006; Harper et al. 2012; Dutta et al. 2014a) and nutrient starvation (Sarathy et al. 2018; Yuan and Sampson 2018) to induce a latent phenotype in Mtb (Via et al. 2008). The Wayne model was one of the

earliest models described whereby bacteria are cultured in sealed containers. Cessation of aeration in the culture results in a decrease in dissolved oxygen concentration resulting in a shift towards hypoxia. After an extended duration of growth arrest, the bacteria could re-enter logarithmic growth if the cultures are aerated. The dormant stage under hypoxic conditions has been termed non-replicating persistence (NRP) and two distinct stages of NRP have been identified. NRP stage I, also described as microaerophilic, is reached when oxygen saturation decreases to 1% and is characterized by growth arrest, steady ATP levels, and increased glycine dehydrogenase production. As oxygen falls below 0.06% saturation, the bacteria enter anaerobic conditions, termed NRP stage II, which is characterized by a decrease in glycine dehydrogenase (Wayne and Hayes 1996; Wayne 2001). NRP stage II exhibits a reversal in the antimicrobial activity of metronidazole whereby the drug shows bactericidal activity in NRP stage II bacilli but is ineffective in aerobically growing bacilli. Based on the Wayne model, hypoxic resazurin reduction assay, as well as MTT assay, has been developed which enables high throughput screening of drugs against latent TB (Martin et al. 2006; Meinzen et al. 2016). A luciferase reporter has also been used to monitor bacterial growth using a protocol similar to the Wayne model. In this method, termed low oxygen recovery assay, the luminescence readout has been used to study the activity of drugs. A red fluorescent protein-expressing *Mtb* has also been used whereby the reporter protein expression could be monitored to determine the stage of bacterial growth (Sohaskey and Voskuil 2015; Gibson et al. 2018). In order to hasten and improve readout, the BACTEC method has also been employed to determine persisters (Kharatmal et al. 2009). Models based on hypoxia-induced dormancy have been most frequently employed; however, others in vitro models such as nutrient deprivation and selective carbon sources have also attracted attention in recent years (Patel et al. 2011; Gibson et al. 2018; Parish 2020). Additionally, nitric oxide and streptomycin have also been used as stressors to induce NRP-like conditions under in vitro conditions. A multi-stress model employing low oxygen and low pH has also been reported (Patel et al. 2011; Gibson et al. 2018; Parish 2020).

We evaluated the in vitro efficacy of satranidazole, a novel nitroimidazole-based bioreductive prodrug, against non-replicating persistent latent *M. tuberculosis* under oxygen depletion and nutrient starvation models/conditions. It exhibited a concentration-dependent effect (2–50 µg/mL) in both models; however, the maximum effect was observed at 50 µg/mL. Moreover, it showed statistically significant activity as compared to metronidazole. However, at lower concentrations (<10 µg/mL), no significant difference was observed between satranidazole and metronidazole. In conclusion, the noteworthy activity of satranidazole against latent *M. tuberculosis* makes it an attractive drug candidate to target latent tuberculosis. Nevertheless, further detailed investigations, along these lines, using suitable animal models of latent tuberculosis are warranted.

**Acknowledgments** We thank the Department of Pharmaceuticals, Ministry of Chemical and Fertilizers, Govt. of India, New Delhi, and Indo-European Union, Seventh Framework Programme (FP-7) for the financial support.

## References

- Abhishek S, Ryndak MB, Choudhary A et al (2019) Transcriptional signatures of mycobacterium tuberculosis in mouse model of intraocular tuberculosis. *Pathog Dis* 77:45
- Actor JK, Olsen M, Jagannath C, Hunter RL (1999) Relationship of survival, organism containment, and granuloma formation in acute murine tuberculosis. *J Interf Cytokine Res* 19:1183–1193
- Agarwal P, Khan SR, Verma SC, Beg M, Singh K, Mitra K et al (2014) Mycobacterium tuberculosis persistence in various adipose depots of infected mice and the effect of anti-tubercular therapy. *Microbes Infect* 16:571–580
- Agarwal P, Pandey P, Sarkar J, Krishnan MY (2016) Mycobacterium tuberculosis can gain access to adipose depots of mice infected via the intra-nasal route and to lungs of mice with an infected subcutaneous fat implant. *Microb Pathog* 93:32–37
- Ahmad Z, Pinn ML, Nuermberger EL, Peloquin CA, Grosset JH, Karakousis PC (2010) The potent bactericidal activity of streptomycin in the guinea pig model of tuberculosis ceases due to the presence of persisters. *J Antimicrob Chemother* 65:2172–2175
- Ahmad Z, Fraig MM, Pinn ML, Tyagi S, Nuermberger EL, Grosset JH et al (2011) Effectiveness of tuberculosis chemotherapy correlates with resistance to mycobacterium tuberculosis infection in animal models. *J Antimicrob Chemother* 66:1560–1566
- Aiyaz M, Bipin C, Pantulwar V, Mugasimangalam R, Shanley CA, Ordway DJ et al (2014) Whole genome response in guinea pigs infected with the high virulence strain mycobacterium tuberculosis tt372. *Tuberculosis* 94:606–615
- Al-Attayah R, El-Shazly A, Mustafa AS (2006) Assessment of in vitro immunity to mycobacterium tuberculosis in a human peripheral blood infection model using a luciferase reporter construct of m. Tuberculosis h37rv. *Clin Exp Immunol* 145:520–527
- Alfonso R, Romero RE, Diaz A, Calderon MN, Urdaneta G, Arce J et al (2004) Isolation and identification of mycobacteria in new world primates maintained in captivity. *Vet Microbiol* 98:285–295
- Alim MA, Sikder S, Bridson TL, Rush CM, Govan BL, Ketheesan N (2017) Anti-mycobacterial function of macrophages is impaired in a diet induced model of type 2 diabetes. *Tuberculosis* 102:47–54
- Alim MA, Sikder S, Sathkumara H, Kupz A, Rush CM, Govan BL et al (2019) Dysregulation of key cytokines may contribute to increased susceptibility of diabetic mice to mycobacterium bovis bcg infection. *Tuberculosis* 115:113–120
- Alim MA, Kupz A, Sikder S, Rush C, Govan B, Ketheesan N (2020) Increased susceptibility to mycobacterium tuberculosis infection in a diet-induced murine model of type 2 diabetes. *Microbes Infect* 22:303–311
- Altaf M, Miller CH, Bellows DS, O'Toole R (2010) Evaluation of the mycobacterium smegmatis and bcg models for the discovery of mycobacterium tuberculosis inhibitors. *Tuberculosis* 90:333–337
- Aly S, Wagner K, Keller C, Malm S, Malzan A, Brandau S et al (2006) Oxygen status of lung granulomas in mycobacterium tuberculosis-infected mice. *J Pathol* 210:298–305
- Amado A, Albuquerque T, Goncalves A, Duarte E, Botelho A, Fernandes T et al (2006) Tuberculosis in mandrills at the lisbon zoo. *Vet Rec* 159:643
- Amin AG, Angala SK, Chatterjee D, Crick DC (2009) Rapid screening of inhibitors of mycobacterium tuberculosis growth using tetrazolium salts. *Methods Mol Biol* 465:187–201
- Andersson JO, Hirt RP, Foster PG, Roger AJ (2006) Evolution of four gene families with patchy phylogenetic distributions: influx of genes into protist genomes. *BMC Ecol Evol* 6:27
- Andrejak C, Almeida DV, Tyagi S, Converse PJ, Ammerman NC, Grosset JH (2015) Characterization of mouse models of mycobacterium avium complex infection and evaluation of drug combinations. *Antimicrob Agents Chemother* 59:2129–2135

- Andreu N, Zelmer A, Sampson SL, Ikeh M, Bancroft GJ, Schaible UE et al (2013) Rapid in vivo assessment of drug efficacy against mycobacterium tuberculosis using an improved firefly luciferase. *J Antimicrob Chemother* 68:2118–2127
- Andreu N, Phelan J, de Sessions PF, Cliff JM, Clark TG, Hibberd ML (2017) Primary macrophages and j774 cells respond differently to infection with mycobacterium tuberculosis. *Sci Rep* 7: 42225
- Arafah S, Kicka S, Trofimov V, Hagedorn M, Andreu N, Wiles S et al (2013) Setting up and monitoring an infection of dictyostelium discoideum with mycobacteria. *Methods Mol Biol* 983:403–417
- Arrey F, Lowe D, Kuhlmann S, Kaiser P, Moura-Alves P, Krishnamoorthy G et al (2019) Humanized mouse model mimicking pathology of human tuberculosis for in vivo evaluation of drug regimens. *Front Immunol* 10:89
- Arthur PK, Amarh V, Cramer P, Arkaijie GB, Blessie EJS, Fuseini MS et al (2019) Characterization of two new multidrug-resistant strains of mycobacterium smegmatis: tools for routine in vitro screening of novel anti-mycobacterial agents. *Antibiotics* 8:4
- Asai M, Li Y, Khara JS, Gladstone CA, Robertson BD, Langford PR et al (2019a) Use of the invertebrate galleria mellonella as an infection model to study the mycobacterium tuberculosis complex. *J Vis Exp* 2019:148
- Asai M, Li Y, Khara JS, Robertson BD, Langford PR, Newton SM (2019b) Galleria mellonella: an infection model for screening compounds against the mycobacterium tuberculosis complex. *Front Microbiol* 10:2630
- Asai M, Li Y, Spiropoulos J, Cooley W, Everest D, Robertson BD et al (2020) A novel biosafety level 2 compliant tuberculosis infection model using a deltaleuddeltapancd double auxotroph of mycobacterium tuberculosis h37rv and galleria mellonella. *Virulence* 11:811–824
- Ault RC, Headley CA, Hare AE, Carruthers BJ, Mejias A, Turner J (2020) Blood rna signatures predict recent tuberculosis exposure in mice, macaques and humans. *Sci Rep* 10:16873
- Aygun C, Ozen H, Kocagoz T, Saribas Z, Aki T, Tekin I (2000) Induction of mycobacteremia by intravesical bacillus calmette-guerin instillation in an experimental animal model and detection with polymerase chain reaction. *J Urol* 163:1588–1590
- Ayyappan JP, Vinnard C, Subbian S, Nagajyothi JF (2018) Effect of mycobacterium tuberculosis infection on adipocyte physiology. *Microbes Infect* 20:81–88
- Ayyappan JP, Ganapathi U, Lizardo K, Vinnard C, Subbian S, Perlin DS et al (2019) Adipose tissue regulates pulmonary pathology during tb infection. *MBio* 10:e02771
- Babrak L, Bermudez LE (2018) Response of the respiratory mucosal cells to mycobacterium avium subsp. Hominissuis microaggregate. *Arch Microbiol* 200:729–742
- Bai X, Kim SH, Azam T, McGibney MT, Huang H, Dinarello CA et al (2010) Il-32 is a host protective cytokine against mycobacterium tuberculosis in differentiated thp-1 human macrophages. *J Immunol* 184:3830–3840
- Ballesteros C, Garrido JM, Vicente J, Romero B, Galindo RC, Minguñon E et al (2009) First data on eurasian wild boar response to oral immunization with bcg and challenge with a mycobacterium bovis field strain. *Vaccine* 27:6662–6668
- Basaraba RJ, Dailey DD, McFarland CT, Shanley CA, Smith EE, McMurray DN et al (2006) Lymphadenitis as a major element of disease in the guinea pig model of tuberculosis. *Tuberculosis* 86:386–394
- Basu S, Rao N, Elkington P (2020) Animal models of ocular tuberculosis: Implications for diagnosis and treatment. *Ocul Immunol Inflamm* 2020:1–7
- Be NA, Lamichhane G, Grosset J, Tyagi S, Cheng QJ, Kim KS et al (2008) Murine model to study the invasion and survival of mycobacterium tuberculosis in the central nervous system. *J Infect Dis* 198:1520–1528
- Be NA, Klinkenberg LG, Bishai WR, Karakousis PC, Jain SK (2011) Strain-dependent cns dissemination in guinea pigs after mycobacterium tuberculosis aerosol challenge. *Tuberculosis* 91:386–389

- Beamer G, Major S, Das B, Campos-Neto A (2014) Bone marrow mesenchymal stem cells provide an antibiotic-protective niche for persistent viable mycobacterium tuberculosis that survive antibiotic treatment. *Am J Pathol* 184:3170–3175
- Bellinger DA, Bullock BC (1988) Cutaneous mycobacterium avium infection in a cynomolgus monkey. *Lab Anim Sci* 38:85–86
- Benard EL, Rougeot J, Racz PI, Spaink HP, Meijer AH (2016) Transcriptomic approaches in the zebrafish model for tuberculosis—insights into host- and pathogen-specific determinants of the innate immune response. *Adv Genet* 95:217–251
- Benmerzoug S, Quesniaux VFJ (2017) Bioengineered 3d models for studying human cell-tuberculosis interactions. *Trends Microbiol* 25:245–246
- Berry SB, Gower MS, Su X, Seshadri C, Theberge AB (2020) A modular microscale granuloma model for immune-microenvironment signaling studies in vitro. *Front Bioeng Biotechnol* 8:931
- Bezoz J, de Juan L, Romero B, Alvarez J, Mazzucchelli F, Mateos A et al (2010) Experimental infection with mycobacterium caprae in goats and evaluation of immunological status in tuberculosis and paratuberculosis co-infected animals. *Vet Immunol Immunopathol* 133:269–275
- Bielecka MK, Tezera LB, Zmijan R, Drobniowski F, Zhang X, Jayasinghe S et al (2017) A bioengineered three-dimensional cell culture platform integrated with microfluidics to address antimicrobial resistance in tuberculosis. *MBio* 8:e02073
- Bishai WR, Dannenberg AM Jr, Parrish N, Ruiz R, Chen P, Zook BC et al (1999) Virulence of mycobacterium tuberculosis cdc1551 and h37rv in rabbits evaluated by lurie’s pulmonary tubercle count method. *Infect Immun* 67:4931–4934
- Blanc L, Daudelin IB, Podell BK, Chen PY, Zimmerman M, Martinot AJ et al (2018a) High-resolution mapping of fluoroquinolones in tb rabbit lesions reveals specific distribution in immune cell types. *elife* 7:e41115
- Blanc L, Sarathy JP, Alvarez Cabrera N, O’Brien P, Dias-Freedman I, Mina M et al (2018b) Impact of immunopathology on the antituberculous activity of pyrazinamide. *J Exp Med* 215:1975–1986
- Blank J, Behrends J, Jacobs T, Schneider BE (2016a) Mycobacterium tuberculosis coinfection has no impact on plasmodium berghei anka-induced experimental cerebral malaria in c57bl/6 mice. *Infect Immun* 84:502–510
- Blank J, Eggers L, Behrends J, Jacobs T, Schneider BE (2016b) One episode of self-resolving plasmodium yoelii infection transiently exacerbates chronic mycobacterium tuberculosis infection. *Front Microbiol* 7:152
- Bodkin GE (1918) A case of tuberculosis in a rat. *J Hyg* 17:10–12
- Bone JF, Soave OA (1970) Experimental tuberculosis in owl monkeys (aotus trivirgatus). *Lab Anim Care* 20:946–948
- Bouz G, Al Hasawi N (2018) The zebrafish model of tuberculosis - no lungs needed. *Crit Rev Microbiol* 44:779–792
- Braian C, Svensson M, Brighenti S, Lerm M, Parasa VR (2015) A 3d human lung tissue model for functional studies on mycobacterium tuberculosis infection. *J Vis Exp* 2015:53084
- Brammer DW, O’Rourke CM, Heath LA, Chrisp CE, Peter GK, Hofing GL (1995) Mycobacterium kansasii infection in squirrel monkeys (saimiri sciureus sciureus). *J Med Primatol* 24:231–235
- Bronczyk LH, Kalter SS (1980) Bacteriological findings in a nonhuman primate colony. *Dev Biol Stand* 45:23–28
- Broussard GW, Ennis DG (2007) Mycobacterium marinum produces long-term chronic infections in medaka: a new animal model for studying human tuberculosis. *Comp Biochem Physiol C Toxicol Pharmacol* 145:45–54
- Broussard GW, Norris MB, Schwindt AR, Fournie JW, Winn RN, Kent ML et al (2009) Chronic mycobacterium marinum infection acts as a tumor promoter in japanese medaka (oryzias latipes). *Comp Biochem Physiol C Toxicol Pharmacol* 149:152–160

- Bruffaerts N, Vluggen C, Roupie V, Duytschaever L, Van den Poel C, Denoel J et al (2017) Virulence and immunogenicity of genetically defined human and porcine isolates of *m. Avium* subsp. *Hominissuis* in an experimental mouse infection. *PLoS One* 12:e0171895
- Bryk R, Mundhra S, Jiang X, Wood M, Pfau D, Weber E et al (2020) Potentiation of rifampin activity in a mouse model of tuberculosis by activation of host transcription factor *eb*. *PLoS Pathog* 16:e1008567
- Bucsan AN, Mehra S, Khader SA, Kaushal D (2019) The current state of animal models and genomic approaches towards identifying and validating molecular determinants of mycobacterium tuberculosis infection and tuberculosis disease. *Pathog Dis* 77:37
- Budell WC, Germain GA, Janisch N, McKie-Krisberg Z, Jayaprakash AD, Resnick AE et al (2020) Transposon mutagenesis in mycobacterium *kansasii* links a small rna gene to colony morphology and biofilm formation and identifies 9,885 intragenic insertions that do not compromise colony outgrowth. *Microbiol Open* 9:e988
- Calderon VE, Valbuena G, Goetz Y, Judy BM, Huante MB, Sutjita P et al (2013) A humanized mouse model of tuberculosis. *PLoS One* 8:e63331
- Capuano SV, Croix DA, Pawar S, Zinovic A, Myers A, Lin PL et al (2003) Experimental mycobacterium tuberculosis infection of cynomolgus macaques closely resembles the various manifestations of human *m. Tuberculosis* infection. *Infect Immun* 71:5831–5844
- Cardona PJ, Williams A (2017) Experimental animal modelling for tb vaccine development. *Int J Infect Dis* 56:268–273
- Cardona PJ, Cooper A, Luquin M, Ariza A, Filipino F, Orme IM et al (1999) The intravenous model of murine tuberculosis is less pathogenic than the aerogenic model owing to a more rapid induction of systemic immunity. *Scand J Immunol* 49:362–366
- Cardona PJ, Gordillo S, Diaz J, Tapia G, Amat I, Pallares A et al (2003) Widespread bronchogenic dissemination makes *dba/2* mice more susceptible than *c57bl/6* mice to experimental aerosol infection with mycobacterium tuberculosis. *Infect Immun* 71:5845–5854
- Carius P, Horstmann JC, de Souza Carvalho-Wodarz C, Lehr CM (2020) Disease models: Lung models for testing drugs against inflammation and infection. *Handb Exp Pharmacol* 265:157
- Carranza-Rosales P, Carranza-Torres IE, Guzman-Delgado NE, Lozano-Garza G, Villarreal-Trevino L, Molina-Torres C et al (2017) Modeling tuberculosis pathogenesis through ex vivo lung tissue infection. *Tuberculosis* 107:126–132
- Carvalho R, de Sonneville J, Stockhammer OW, Savage ND, Veneman WJ, Ottenhoff TH et al (2011) A high-throughput screen for tuberculosis progression. *PLoS One* 6:e16779
- Cavaleri M, Manolis E (2015) Hollow fiber system model for tuberculosis: the European medicines agency experience. *Clin Infect Dis* 61(1):1–4
- Cha SB, Jeon BY, Kim WS, Kim JS, Kim HM, Kwon KW et al (2015) Experimental reactivation of pulmonary mycobacterium *avium* complex infection in a modified cornell-like murine model. *PLoS One* 10:e0139251
- Chackerian AA, Behar SM (2003) Susceptibility to mycobacterium tuberculosis: lessons from inbred strains of mice. *Tuberculosis* 83:279–285
- Chackerian AA, Perera TV, Behar SM (2001) Gamma interferon-producing *cd4+* t lymphocytes in the lung correlate with resistance to infection with mycobacterium tuberculosis. *Infect Immun* 69:2666–2674
- Chambers MA, Williams A, Gavier-Widen D, Whelan A, Hughes C, Hall G et al (2001) A guinea pig model of low-dose mycobacterium *bovis* aerogenic infection. *Vet Microbiol* 80:213–226
- Chaparas SD, Hedrick SR, Clark RG, Garman R (1970) Comparison of the lymphocyte transformation test with the tuberculin test in rhesus monkeys and chimpanzees. *Am J Vet Res* 31:1437–1441
- Chaturvedi V, Jyoti D, Srivastava S, Gupta HP (1999) Secretory proteins of mycobacterium *habana* induce a protective immune response against experimental tuberculosis. *FEMS Immunol Med Microbiol* 26:143–151
- Chaudhuri M, Squibb RL, Solotorovsky M (1980) Effects of glucose and fructose loading on glycogenesis in chicks infected with avian tuberculosis. *Poult Sci* 59:1736–1741

- Chege GK, Warren RM, Gey NC, van Pittius WA, Burgers, Wilkinson RJ, Shephard EG et al (2008) Detection of natural infection with mycobacterium intracellulare in healthy wild-caught chacma baboons (*papio ursinus*) by esat-6 and cfp-10 ifn-gamma elispot tests following a tuberculosis outbreak. *BMC Microbiol* 8:27
- Chen Z, Shao XY, Wang C, Hua MH, Wang CN, Wang X et al (2018) Mycobacterium marinum infection in zebrafish and microglia imitates the early stage of tuberculous meningitis. *J Mol Neurosci* 64:321–330
- Cheng T, Kam JY, Johansen MD, Oehlers SH (2020) High content analysis of granuloma histology and neutrophilic inflammation in adult zebrafish infected with mycobacterium marinum. *Micron* 129:102782
- Chingwaru W, Glashoff RH, Vidmar J, Kapewangolo P, Sampson SL (2016) Mammalian cell cultures as models for mycobacterium tuberculosis-human immunodeficiency virus (hiv) interaction studies: a review. *Asian Pac J Trop Med* 9:832–838
- Chrisp CE, Cohen BJ, Ringler DH, Abrams GD (1968) Tuberculosis in a squirrel monkey (*saimiri sciureus*). *J Am Vet Med Assoc* 153:918–922
- Churchill GA, Airey DC, Allayee H, Angel JM, Attie AD, Beatty J et al (2004) The collaborative cross, a community resource for the genetic analysis of complex traits. *Nat Genet* 36:1133–1137
- Churchill GA, Gatti DM, Munger SC, Svenson KL (2012) The diversity outbred mouse population. *Mamm Genome* 23:713–718
- Clarke KA, Fitzgerald SD, Zwick LS, Church SV, Kaneene JB, Wismer AR et al (2007) Experimental inoculation of meadow voles (*microtus pennsylvanicus*), house mice (*mus musculus*), and norway rats (*rattus norvegicus*) with mycobacterium bovis. *J Wildl Dis* 43:353–365
- Clemens DL, Lee BY, Silva A, Dillon BJ, Maslesa-Galic S, Nava S et al (2019) Artificial intelligence enabled parabolic response surface platform identifies ultra-rapid near-universal tb drug treatment regimens comprising approved drugs. *PLoS One* 14:e0215607
- Cohen SB, Gern BH, Delahaye JL, Adams KN, Plumlee CR, Winkler JK et al (2018) Alveolar macrophages provide an early mycobacterium tuberculosis niche and initiate dissemination. *Cell Host Microbe* 24:439–446
- Cohen A, Mathiasen VD, Schon T, Wejse C (2019) The global prevalence of latent tuberculosis: a systematic review and meta-analysis. *Eur Respir J* 54:1900655
- Coleman MT, Chen RY, Lee M, Lin PL, Dodd LE, Maiello P et al (2014a) Pet/ct imaging reveals a therapeutic response to oxazolidinones in macaques and humans with tuberculosis. *Sci Transl Med* 6:265
- Coleman MT, Maiello P, Tomko J, Frye LJ, Fillmore D, Janssen C et al (2014b) Early changes by (18)fluorodeoxyglucose positron emission tomography coregistered with computed tomography predict outcome after mycobacterium tuberculosis infection in cynomolgus macaques. *Infect Immun* 82:2400–2404
- Collins FM, Auclair L, Montalbino V (1975) Effect of t-cell depletion on the growth of bcg in the mouse footpad. *Int Arch Allergy Appl Immunol* 48:680–690
- Collymore C, Kent L, Ahn SK, Xu W, Li M, Liu J et al (2018) Humane endpoints for guinea pigs used for mycobacterium tuberculosis vaccine research. *Comp Med* 68:41–47
- Commandeur S, Iakobachvili N, Sparrius M, Nur MM, Mukamolova GV, Bitter W (2020) Zebrafish embryo model for assessment of drug efficacy on mycobacterial persisters. *Antimicrob Agents Chemother* 64:e00801
- Cooke MM, Alley MR, Manktelow BW (2003) Experimental infection with BCG as a model of tuberculosis in the brushtail possum (*trichosurus vulpecula*). *N Z Vet J* 51:132–138
- Corleis B, Bucsan AN, Deruaz M, Vrbanac VD, Lisanti-Park AC, Gates SJ et al (2019) Hiv-1 and siv infection are associated with early loss of lung interstitial cd4+ t cells and dissemination of pulmonary tuberculosis. *Cell Rep* 26:1409–1418
- Corner LA, Pfeiffer DU, Morris RS (2003) Social-network analysis of mycobacterium bovis transmission among captive brushtail possums (*trichosurus vulpecula*). *Prev Vet Med* 59:147–167



- Coscolla M, Lewin A, Metzger S, Maetz-Rennsing K, Calvignac-Spencer S, Nitsche A et al (2013) Novel mycobacterium tuberculosis complex isolate from a wild chimpanzee. *Emerg Infect Dis* 19:969–976
- Cosma CL, Swaim LE, Volkman H, Ramakrishnan L, Davis JM (2006) Zebrafish and frog models of mycobacterium marinum infection. *Curr Protoc Microbiol* 10:10–12
- Costa SS, Lopes E, Azzali E, Machado D, Coelho T, da Silva PE et al (2016) An experimental model for the rapid screening of compounds with potential use against mycobacteria. *Assay Drug Dev Technol* 14:524–534
- Cross GB, Yeo BC, Hutchinson PE, Tan MC, Verma R, Lu Q et al (2019) Impact of selective immune-cell depletion on growth of mycobacterium tuberculosis (mtb) in a whole-blood bactericidal activity (wba) assay. *PLoS One* 14:e0216616
- Crouser ED, White P, Caceres EG, Julian MW, Papp AC, Locke LW et al (2017) A novel in vitro human granuloma model of sarcoidosis and latent tuberculosis infection. *Am J Respir Cell Mol Biol* 57:487–498
- Cui Z, Wang J, Lu J, Huang X, Zheng R, Hu Z (2013) Evaluation of methods for testing the susceptibility of clinical mycobacterium tuberculosis isolates to pyrazinamide. *J Clin Microbiol* 51:1374–1380
- Cummings MM, Hudgins PC, Whorton MC, Sheldon WH (1952) The influence of cortisone and streptomycin on experimental tuberculosis in the albino rat. *Am Rev Tuberc* 65:596–602
- Cyktor JC, Carruthers B, Kominsky RA, Beamer GL, Stromberg P, Turner J (2013) Il-10 inhibits mature fibrotic granuloma formation during mycobacterium tuberculosis infection. *J Immunol* 190:2778–2790
- da Silva DA, Rego AM, Ferreira NV, de Andrade MAS, Campelo AR, Caldas PCS et al (2017) Detection of mycobacterial infection in non-human primates using the xpert mtb/rif molecular assay. *Tuberculosis* 107:59–62
- Daigeler A (1952) The cotton rat (*sigmodon hispidus hispidus*) as an experimental animal in the diagnosis of tuberculosis. *Z Hyg Infekt* 135:588–591
- Das B, Kashino SS, Pulu I, Kalita D, Swami V, Yeger H et al (2013) Cd271(+) bone marrow mesenchymal stem cells may provide a niche for dormant mycobacterium tuberculosis. *Sci Transl Med* 5:170ra113
- Davis JM, Ramakrishnan L (2009) The role of the granuloma in expansion and dissemination of early tuberculous infection. *Cell* 136:37–49
- de Arruda MS, Montenegro MR (1995) The hamster cheek pouch: an immunologically privileged site suitable to the study of granulomatous infections. *Rev Inst Med Trop Sao Paulo* 37:303–309
- De Groote MA, Gilliland JC, Wells CL, Brooks EJ, Woolhiser LK, Gruppo V et al (2011) Comparative studies evaluating mouse models used for efficacy testing of experimental drugs against mycobacterium tuberculosis. *Antimicrob Agents Chemother* 55:1237–1247
- De Klerk L, Michel AL, Grobler DG, Bengis RG, Bush M, Kriek NP et al (2006) An experimental intratracheal infection model for bovine tuberculosis in african buffaloes, *syncerus caffer*. *Onderstepoort J Vet Res* 73:293–303
- de Knecht GJ, Dickinson L, Pertinez H, Evangelopoulos D, McHugh TD, Bakker-Woudenberg I et al (2017) Assessment of treatment response by colony forming units, time to culture positivity and the molecular bacterial load assay compared in a mouse tuberculosis model. *Tuberculosis* 105:113–118
- de Val Perez B, Lopez-Soria S, Nofrarias M, Martin M, Vordermeier HM, Villarreal-Ramos B et al (2011) Experimental model of tuberculosis in the domestic goat after endobronchial infection with mycobacterium caprae. *Clin Vaccine Immunol* 18:1872–1881
- Dean GS, Rhodes SG, Coad M, Whelan AO, Wheeler P, Villarreal-Ramos B et al (2008) Isoniazid treatment of mycobacterium bovis in cattle as a model for human tuberculosis. *Tuberculosis* 88: 586–594
- Defraigne V, Fauvart M, Michiels J (2018) Fighting bacterial persistence: current and emerging anti-persister strategies and therapeutics. *Drug Resist Updat* 38:12–26

- Deinard AS, Lerche NW, Smith DG (2002) Polymorphism in the rhesus macaque (*macaca mulatta*) *nrampl1* gene: Lack of an allelic association to tuberculosis susceptibility. *J Med Primatol* 31:8–16
- Dennis EW, Gaboe FC (1949) Experimental tuberculosis of the syrian hamster, *cricetus auratus*. *Ann N Y Acad Sci* 52:646–661
- Dessau FI, Yeager RL, Kulish M (1949) A simplified guinea pig test for tuberculostatic agents. *Am Rev Tuberc* 60:223–227
- Diedrich CR, Rutledge T, Maiello P, Baranowski TM, White AG, Borish HJ et al (2020) *Siv* and mycobacterium tuberculosis synergy within the granuloma accelerates the reactivation pattern of latent tuberculosis. *PLoS Pathog* 16:e1008413
- Dijkman K, Vervenne RAW, Sombroek CC, Boot C, Hofman SO, van Meijgaarden KE et al (2019) Disparate tuberculosis disease development in macaque species is associated with innate immunity. *Front Immunol* 10:2479
- Dionne MS, Ghori N, Schneider DS (2003) *Drosophila melanogaster* is a genetically tractable model host for mycobacterium marinum. *Infect Immun* 71:3540–3550
- Domingues-Junior M, Pinheiro SR, Guerra JL, Palermo-Neto J (2000) Effects of treatment with amphetamine and diazepam on mycobacterium bovis-induced infection in hamsters. *Immunopharmacol Immunotoxicol* 22:555–574
- Dong H, Jing W, Yabo Y, Xiaokang Y, Wan W, Min M et al (2014) Establishment of rat model of silicotuberculosis and its pathological characteristic. *Pathog Glob Health* 108:312–316
- Dong H, Lv Y, Sreevatsan S, Zhao D, Zhou X (2017) Differences in pathogenicity of three animal isolates of mycobacterium species in a mouse model. *PLoS One* 12:e0183666
- Donnelly CA, Nouvellet P (2013) The contribution of badgers to confirmed tuberculosis in cattle in high-incidence areas in england. *PLoS Curr* 5:776098
- Dorman SE, Hatem CL, Tyagi S, Aird K, Lopez-Molina J, Pitt ML et al (2004) Susceptibility to tuberculosis: clues from studies with inbred and outbred New Zealand white rabbits. *Infect Immun* 72:1700–1705
- Dormans J, Burger M, Aguilar D, Hernandez-Pando R, Kremer K, Roholl P et al (2004) Correlation of virulence, lung pathology, bacterial load and delayed type hypersensitivity responses after infection with different mycobacterium tuberculosis genotypes in a balb/c mouse model. *Clin Exp Immunol* 137:460–468
- Driver ER, Ryan GJ, Hoff DR, Irwin SM, Basaraba RJ, Kramnik I et al (2012) Evaluation of a mouse model of necrotic granuloma formation using *c3heb/fej* mice for testing of drugs against mycobacterium tuberculosis. *Antimicrob Agents Chemother* 56:3181–3195
- Duffy FJ, Weiner J, Hansen S, Tabb DL, Suliman S, Thompson E et al (2019) Immunometabolic signatures predict risk of progression to active tuberculosis and disease outcome. *Front Immunol* 10:527
- Duque C, Arroyo L, Ortega H, Montufar F, Ortiz B, Rojas M et al (2014) Different responses of human mononuclear phagocyte populations to mycobacterium tuberculosis. *Tuberculosis* 94:111–122
- Durkee MS, Cirillo JD, Maitland KC (2019) Fluorescence modeling of in vivo optical detection of mycobacterium tuberculosis. *Biomed Opt Express* 10:5445–5460
- Dutta NK, Illei PB, Jain SK, Karakousis PC (2014a) Characterization of a novel necrotic granuloma model of latent tuberculosis infection and reactivation in mice. *Am J Pathol* 184:2045–2055
- Dutta NK, McLachlan J, Mehra S, Kaushal D (2014b) Humoral and lung immune responses to mycobacterium tuberculosis infection in a primate model of protection. *Trials Vaccinol* 3:47–51
- Ehlers LP, Bianchi MV, Argenta FF, Lopes BC, Taunde PA, Wagner PGC et al (2020) Mycobacterium tuberculosis var. *Tuberculosis* infection in two captive black capuchins (*sapajus nigritus*) in southern brazil. *Braz J Microbiol* 51:2169–2173
- El-Etr SH, Yan L, Cirillo JD (2001) Fish monocytes as a model for mycobacterial host-pathogen interactions. *Infect Immun* 69:7310–7317
- Ellis H, Mulder C, Valverde E, Poling A, Edwards T (2017) Reproducibility of african giant pouched rats detecting mycobacterium tuberculosis. *BMC Infect Dis* 17:298

- Elwood RL, Wilson S, Blanco JC, Yim K, Pletneva L, Nikonenko B et al (2007) The American cotton rat: a novel model for pulmonary tuberculosis. *Tuberculosis* 87:145–154
- Engel GA, Wilbur AK, Westmark A, Horn D, Johnson J, Jones-Engel L (2012) Naturally acquired mycobacterium tuberculosis complex in laboratory pig-tailed macaques. *Emerg Microbes Infect* 1:e30
- Entwistle FM, Coote PJ (2018) Evaluation of greater wax moth larvae, *Galleria mellonella*, as a novel in vivo model for non-tuberculosis mycobacteria infections and antibiotic treatments. *J Med Microbiol* 67:585–597
- Eruslanov EB, Majorov KB, Orlova MO, Mischenko VV, Kondratieva TK, Apt AS et al (2004) Lung cell responses to *M. tuberculosis* in genetically susceptible and resistant mice following intratracheal challenge. *Clin Exp Immunol* 135:19–28
- Esaulova E, Das S, Singh DK, Chorenno-Parra JA, Swain A, Arthur L et al (2020) The immune landscape in tuberculosis reveals populations linked to disease and latency. *Cell Host Microbe* 29:165–178
- Eskuchen (1952) Diagnosis of tuberculosis with guinea pigs and gold hamster. *Tuberkulosearzt* 6: 356–358
- Evans S, Butler JR, Mattila JT, Kirschner DE (2020) Systems biology predicts that fibrosis in tuberculous granulomas may arise through macrophage-to-myofibroblast transformation. *PLoS Comput Biol* 16:e1008520
- Fatima S, Kamble SS, Dwivedi VP, Bhattacharya D, Kumar S, Ranganathan A et al (2020) Mycobacterium tuberculosis programs mesenchymal stem cells to establish dormancy and persistence. *J Clin Invest* 130:655–661
- Fenwick NI (2012) Modelled impacts of badger culling on cattle tb in a real area with geographic boundaries. *Vet Rec* 170:177
- Florido M, Grima MA, Gillis CM, Xia Y, Turner SJ, Triccas JA et al (2013) Influenza a virus infection impairs mycobacteria-specific t cell responses and mycobacterial clearance in the lung during pulmonary coinfection. *J Immunol* 191:302–311
- Flynn JL, Gideon HP, Mattila JT, Lin PL (2015) Immunology studies in non-human primate models of tuberculosis. *Immunol Rev* 264:60–73
- Forget A, Skamene E, Gros P, Mialhe AC, Turcotte R (1981) Differences in response among inbred mouse strains to infection with small doses of mycobacterium bovis bcg. *Infect Immun* 32:42–47
- Fourie PB, Odendaal MW (1983) Mycobacterium tuberculosis in a closed colony of baboons (*Papio ursinus*). *Lab Anim* 17:125–128
- Fox JG, Campbell LH, Snyder SB, Reed C, Soave OA (1974) Tuberculous spondylitis and pott's paraplegia in a rhesus monkey (*Macaca mulatta*). *Lab Anim Sci* 24:335–339
- Franzblau SG, DeGroot MA, Cho SH, Andries K, Nuermberger E, Orme IM et al (2012) Comprehensive analysis of methods used for the evaluation of compounds against mycobacterium tuberculosis. *Tuberculosis* 92:453–488
- Fremming BD, Benson RE, Young RJ, Harris MD Jr (1957) Antituberculous therapy in macaca mulatta monkeys. *Am Rev Tuberc* 76:225–231
- Fujita M, Harada E, Matsumoto T, Mizuta Y, Ikegame S, Ouchi H et al (2010) Impaired host defence against mycobacterium avium in mice with chronic granulomatous disease. *Clin Exp Immunol* 160:457–460
- Fulford GR, Roberts MG, Heesterbeek JA (2002) The metapopulation dynamics of an infectious disease: tuberculosis in possums. *Theor Popul Biol* 61:15–29
- Galbadage T, Shepherd TF, Cirillo SL, Gumienny TL, Cirillo JD (2016) The caenorhabditis elegans p38 mapk gene plays a key role in protection from mycobacteria. *Microbiol Open* 5:436–452
- Ganatra SR, Bucsan AN, Alvarez X, Kumar S, Chatterjee A, Quezada M et al (2020) Antiretroviral therapy does not reduce tuberculosis reactivation in a tuberculosis-hiv coinfection model. *J Clin Invest* 130:5171–5179
- Gaonkar S, Bharath S, Kumar N, Balasubramanian V, Shandil RK (2010) Aerosol infection model of tuberculosis in wistar rats. *Int J Microbiol* 2010:426035

- Garcia EA, Blanco FC, Muniz XF, Eirin ME, Klepp LI, Bigi F (2020) Elimination of esat-6 and cfp-10 from a candidate vaccine against bovine tuberculosis impaired its protection efficacy in the balbc mouse model. *Int J Mycobacteriol* 9:417–421
- Garcia-Pelayo MC, Bachy VS, Kaveh DA, Hogarth PJ (2015) Balb/c mice display more enhanced bcg vaccine induced th1 and th17 response than c57bl/6 mice but have equivalent protection. *Tuberculosis* 95:48–53
- Garcia-Pelayo MC, Kaveh DA, Sibly L, Webb PR, Bull NC, Cutting SM et al (2016) Boosting bcg with inert spores improves immunogenicity and induces specific il-17 responses in a murine model of bovine tuberculosis. *Tuberculosis* 98:97–103
- Garhyan J, Bhuyan S, Pulu I, Kalita D, Das B, Bhatnagar R (2015) Preclinical and clinical evidence of mycobacterium tuberculosis persistence in the hypoxic niche of bone marrow mesenchymal stem cells after therapy. *Am J Pathol* 185:1924–1934
- Gasso D, Vicente J, Mentaberre G, Soriguer R, Jimenez Rodriguez R, Navarro-Gonzalez N et al (2016) Oxidative stress in wild boars naturally and experimentally infected with mycobacterium bovis. *PLoS One* 11:e0163971
- Gautam US, Foreman TW, Bucsan AN, Veatch AV, Alvarez X, Adekambi T et al (2018) In vivo inhibition of tryptophan catabolism reorganizes the tuberculoma and augments immune-mediated control of mycobacterium tuberculosis. *Proc Natl Acad Sci U S A* 115:E62–E71
- Geng G, Wang Q, Shi J, Yan J, Niu N, Wang Z (2015) Establishment of a new zealand rabbit model of spinal tuberculosis. *J Spinal Disord Tech* 28:140–145
- Gharpure PV (1945) Guinea-pig inoculation in the diagnosis of tuberculosis. *Ind Med Gaz* 80:327
- Gibson SER, Harrison J, Cox JAG (2018) Modelling a silent epidemic: a review of the in vitro models of latent tuberculosis. *Pathogens* 7:88
- Gideon HP, Phuah J, Myers AJ, Bryson BD, Rodgers MA, Coleman MT et al (2015) Variability in tuberculosis granuloma t cell responses exists, but a balance of pro- and anti-inflammatory cytokines is associated with sterilization. *PLoS Pathog* 11:e1004603
- Gideon HP, Skinner JA, Baldwin N, Flynn JL, Lin PL (2016) Early whole blood transcriptional signatures are associated with severity of lung inflammation in cynomolgus macaques with mycobacterium tuberculosis infection. *J Immunol* 197:4817–4828
- Gil O, Diaz I, Vilaplana C, Tapia G, Diaz J, Fort M et al (2010) Granuloma encapsulation is a key factor for containing tuberculosis infection in minipigs. *PLoS One* 5:e10030
- Glover RE (1946) Susceptibility of the golden hamster (cricetus auratus) to mycobacterium tuberculosis hominis and bovis. *J Pathol Bacteriol* 58:107–110
- Gong W, Liang Y, Wu X (2020) Animal models of tuberculosis vaccine research: an important component in the fight against tuberculosis. *Biomed Res Int* 2020:4263079
- Gormley E, Corner LAL (2017) Pathogenesis of mycobacterium bovis infection: the badger model as a paradigm for understanding tuberculosis in animals. *Front Vet Sci* 4:247
- Gormus BJ, Blanchard JL, Alvarez XH, Didier PJ (2004) Evidence for a rhesus monkey model of asymptomatic tuberculosis. *J Med Primatol* 33:134–145
- Goyal RK (1938) The guinea-pig in the laboratory diagnosis of tuberculosis. *Ind Med Gaz* 73:282–283
- Green DM, Kiss IZ, Mitchell AP, Kao RR (2008) Estimates for local and movement-based transmission of bovine tuberculosis in british cattle. *Proc Biol Sci* 275:1001–1005
- Griffin JF, Rodgers CR, Liggett S, Mackintosh CG (2006) Tuberculosis in ruminants: characteristics of intra-tonsillar mycobacterium bovis infection models in cattle and deer. *Tuberculosis* 86:404–418
- Grossman TH, Shoen CM, Jones SM, Jones PL, Cynamon MH, Locher CP (2015) The efflux pump inhibitor timcodar improves the potency of antimycobacterial agents. *Antimicrob Agents Chemother* 59:1534–1541
- Grover A, Troy A, Rowe J, Trout JM, Creissen E, McLean J et al (2017) Humanized nog mice as a model for tuberculosis vaccine-induced immunity: a comparative analysis with the mouse and guinea pig models of tuberculosis. *Immunology* 152:150–162

- Grumbach F (1960) Experimental antituberculous chemotherapy in the white rat. *Ann Inst Pasteur* 98:485–493
- Grumbach F, Canetti G, Grosset J, le Lirzin M (1967) Late results of long-term intermittent chemotherapy of advanced, murine tuberculosis: limits of the murine model. *Tubercle* 48:11–26
- Guirado E, Gordillo S, Gil O, Diaz J, Tapia G, Vilaplana C et al (2006) Intragranulomatous necrosis in pulmonary granulomas is not related to resistance against mycobacterium tuberculosis infection in experimental murine models induced by aerosol. *Int J Exp Pathol* 87:139–149
- Guirado E, Schlesinger LS, Kaplan G (2013) Macrophages in tuberculosis: friend or foe. *Semin Immunopathol* 35:563–583
- Gumbo T, Pasipanodya JG, Nuermberger E, Romero K, Hanna D (2015a) Correlations between the hollow fiber model of tuberculosis and therapeutic events in tuberculosis patients: learn and confirm. *Clin Infect Dis* 61(1):18–24
- Gumbo T, Pasipanodya JG, Romero K, Hanna D, Nuermberger E (2015b) Forecasting accuracy of the hollow fiber model of tuberculosis for clinical therapeutic outcomes. *Clin Infect Dis* 61(1): 25–31
- Guo Q, Bi J, Wang H, Zhang X (2021) Mycobacterium tuberculosis esx-1-secreted substrate protein *espc* promotes mycobacterial survival through endoplasmic reticulum stress-mediated apoptosis. *Emerg Microbes Infect* 10:19–36
- Gupta A, Bhakta S (2012) An integrated surrogate model for screening of drugs against mycobacterium tuberculosis. *J Antimicrob Chemother* 67:1380–1391
- Gupta SK, Mathur IS (1969) A cheap and quick method of screening potential antimycobacterial agents in the syrian or golden hamster (*Cricetus auratus*). *Experientia* 25:782–783
- Gupta A, Bhakta S, Kundu S, Gupta M, Srivastava BS, Srivastava R (2009) Fast-growing, non-infectious and intracellularly surviving drug-resistant mycobacterium *aurum*: a model for high-throughput antituberculosis drug screening. *J Antimicrob Chemother* 64:774–781
- Gupta A, Ahmad FJ, Ahmad F, Gupta UD, Natarajan M, Katoch V et al (2012) Efficacy of mycobacterium indicus pranii immunotherapy as an adjunct to chemotherapy for tuberculosis and underlying immune responses in the lung. *PLoS One* 7:e39215
- Gupta UD, Abbas A, Kashyap RP, Gupta P (2016) Murine model of tb meningitis. *Int J Mycobacteriol* 5(Suppl 1):S178
- Hagedorn M, Soldati T (2007) Flotillin and racth modulate the intracellular immunity of dictyostelium to mycobacterium marinum infection. *Cell Microbiol* 9:2716–2733
- Harjula SE, Saralahti AK, Ojanen MJT, Rantaperi T, Uusi-Makela MIE, Nykter M et al (2020) Characterization of immune response against mycobacterium marinum infection in the main hematopoietic organ of adult zebrafish (*Danio rerio*). *Dev Comp Immunol* 103:103523
- Harper J, Skerry C, Davis SL, Tasneen R, Weir M, Kramnik I et al (2012) Mouse model of necrotic tuberculosis granulomas develops hypoxic lesions. *J Infect Dis* 205:595–602
- Haug M, Awuh JA, Steigedal M, Frengen Kojen J, Marstad A, Nordrum IS et al (2013) Dynamics of immune effector mechanisms during infection with mycobacterium avium in c57bl/6 mice. *Immunology* 140:232–243
- Henao J, Sanchez D, Munoz CH, Mejia N, Arias MA, Garcia LF et al (2007) Human splenic macrophages as a model for in vitro infection with mycobacterium tuberculosis. *Tuberculosis* 87:509–517
- Henao-Tamayo M, Obregon-Henao A, Creissen E, Shanley C, Orme I, Ordway DJ (2015) Differential mycobacterium bovis bcg vaccine-derived efficacy in c3heb/fej and c3h/heaouj mice exposed to a clinical strain of mycobacterium tuberculosis. *Clin Vaccine Immunol* 22:91–98
- Heng Y, Seah PG, Siew JY, Tay HC, Singhal A, Mathys V et al (2011) Mycobacterium tuberculosis infection induces hypoxic lung lesions in the rat. *Tuberculosis* 91:339–341
- Henrich M, Moser I, Weiss A, Reinacher M (2007) Multiple granulomas in three squirrel monkeys (*Saimiri sciureus*) caused by mycobacterium microti. *J Comp Pathol* 137:245–248
- Hernandez Pando R, Aguilar D, Cohen I, Guerrero M, Ribon W, Acosta P et al (2010) Specific bacterial genotypes of mycobacterium tuberculosis cause extensive dissemination and brain infection in an experimental model. *Tuberculosis* 90:268–277

- Hernandez-Pando R, Aguilar D, Orozco H, Cortez Y, Brunet LR, Rook GA (2008) Orally administered mycobacterium vaccae modulates expression of immunoregulatory molecules in balb/c mice with pulmonary tuberculosis. *Clin Vaccine Immunol* 15:1730–1736
- Hessler JR, Moreland AF (1968) Pulmonary tuberculosis in a squirrel monkey (*saimiri sciureus*). *J Am Vet Med Assoc* 153:923–927
- Heuts F, Gavier-Widen D, Carow B, Juarez J, Wigzell H, Rottenberg ME (2013) Cd4+ cell-dependent granuloma formation in humanized mice infected with mycobacteria. *Proc Natl Acad Sci U S A* 110:6482–6487
- Heywood R, Medd RK, Street AE (1970) The early clinical diagnosis of tuberculosis in baboons. *Br Vet J* 126:372–382
- Hino M, Oda M, Yoshida A, Nakata K, Kohchi C, Nishizawa T et al (2005) Establishment of an in vitro model using nr8383 cells and mycobacterium bovis calmette-guerin that mimics a chronic infection of mycobacterium tuberculosis. *In Vivo* 19:821–830
- Hirota K, Hasegawa T, Nakajima T, Inagawa H, Kohchi C, Soma G et al (2010) Delivery of rifampicin-plga microspheres into alveolar macrophages is promising for treatment of tuberculosis. *J Control Release* 142:339–346
- Ho VQT, Verboom T, Rong MK, Habjan E, Bitter W, Speer A (2021) Heterologous expression of etha and katg in mycobacterium marinum enables the rapid identification of new prodrugs active against mycobacterium tuberculosis. *Antimicrob Agents Chemother* 65(4):e01445
- Hodgkinson JW, Ge JQ, Grayfer L, Stafford J, Belosevic M (2012) Analysis of the immune response in infections of the goldfish (*carassius auratus* l.) with mycobacterium marinum. *Dev Comp Immunol* 38:456–465
- Hogset H, Horgan CC, Armstrong JPK, Bergholt MS, Torraca V, Chen Q et al (2020) In vivo biomolecular imaging of zebrafish embryos using confocal raman spectroscopy. *Nat Commun* 11:6172
- Hosseini R, Lamers GEM, Bos E, Hogendoorn PCW, Koster AJ, Meijer AH et al (2021) The adapter protein myd88 plays an important role in limiting mycobacterial growth in a zebrafish model for tuberculosis. *Virchows Arch* 479(2):265–275
- Huante MB, Saito TB, Nusbaum RJ, Naqvi KF, Chauhan S, Hunter RL et al (2020) Small animal model of post-chemotherapy tuberculosis relapse in the setting of hiv co-infection. *Front Cell Infect Microbiol* 10:150
- Hudock TA, Lackner AA, Kaushal D (2014) Microdissection approaches in tuberculosis research. *J Med Primatol* 43:294–297
- Hudock TA, Foreman TW, Bandyopadhyay N, Gautam US, Veatch AV, LoBato DN et al (2017) Hypoxia sensing and persistence genes are expressed during the intragranulomatous survival of mycobacterium tuberculosis. *Am J Respir Cell Mol Biol* 56:637–647
- Husain AA, Gupta UD, Gupta P, Nayak AR, Chandak NH, Dagainawla HF et al (2017) Modelling of cerebral tuberculosis in balb/c mice using clinical strain from patients with cns tuberculosis infection. *Indian J Med Res* 145:833–839
- Hussel L (1951) Suitability of the golden hamster as laboratory animal in tuberculosis diagnosis. *Zentralbl Bakteriolog Orig* 156:445–450
- Hyoek RK, Robert J (2019) A xenopus tadpole alternative model to study innate-like t cell-mediated anti-mycobacterial immunity. *Dev Comp Immunol* 92:253–259
- Iacobino A, Fattorini L, Giannoni F (2020) Drug-resistant tuberculosis 2020: Where we stand. *Appl Sci* 10:2153
- Idh J, Andersson B, Lerm M, Raffetseder J, Eklund D, Woksepp H et al (2017) Reduced susceptibility of clinical strains of mycobacterium tuberculosis to reactive nitrogen species promotes survival in activated macrophages. *PLoS One* 12:e0181221
- Indzhiia LV, Yakovleva LA, Simovonjan VG, Dshikidze EK, Kovaljova VI, Popova VN (1977) The character and results of comparative experimental therapy of tuberculosis in macaca arctoides monkeys. *Z Versuchstierkd* 19:13–25

- Jain N, Kalam H, Singh L, Sharma V, Kedia S, Das P et al (2020) Mesenchymal stem cells offer a drug-tolerant and immune-privileged niche to mycobacterium tuberculosis. *Nat Commun* 11: 3062
- Javed S, Marsay L, Wareham A, Lewandowski KS, Williams A, Dennis MJ et al (2016) Temporal expression of peripheral blood leukocyte biomarkers in a macaca fascicularis infection model of tuberculosis; comparison with human datasets and analysis with parametric/non-parametric tools for improved diagnostic biomarker identification. *PLoS One* 11:e0154320
- Jespersen A (1974) Infection of arvicola terrestris (vole rat) with m. Tuberculosis and m. Bovis. *Acta Pathol Microbiol Scand B: Microbiol Immunol* 82:667–675
- Jhamb SS, Singh PP (2009) A short-term model for preliminary screening of potential anti-tubercular compounds. *Scand J Infect Dis* 41:886–889
- Jhamb SS, Goyal A, Singh PP (2014) Determination of the activity of standard anti-tuberculosis drugs against intramacrophage mycobacterium tuberculosis, in vitro: Mgit 960 as a viable alternative for bactec 460. *Braz J Infect Dis* 18:336–340
- Joardar SN, Ram GC, Goswami T (2002) Dynamic changes in cellular immune responses in experimental bovine tuberculosis. *Med Sci Monit* 8:471–480
- Johansen MD, Kasparian JA, Hortle E, Britton WJ, Purdie AC, Oehlers SH (2018) Mycobacterium marinum infection drives foam cell differentiation in zebrafish infection models. *Dev Comp Immunol* 88:169–172
- Junqueira-Kipnis AP, de Oliveira FM, Trentini MM, Tiwari S, Chen B, Resende DP et al (2013) Prime-boost with mycobacterium smegmatis recombinant vaccine improves protection in mice infected with mycobacterium tuberculosis. *PLoS One* 8:e78639
- Kager LM, Runge JH, Nederveen AJ, Roelofs JJ, Stoker J, Maas M et al (2014) A new murine model to study musculoskeletal tuberculosis. *Tuberculosis* 94:306–310
- Kannan N, Haug M, Steigedal M, Flo TH (2020) Mycobacterium smegmatis vaccine vector elicits cd4+ th17 and cd8+ tc17 t cells with therapeutic potential to infections with mycobacterium avium. *Front Immunol* 11:1116
- Kao RR, Roberts MG, Ryan TJ (1997) A model of bovine tuberculosis control in domesticated cattle herds. *Proc Biol Sci* 264:1069–1076
- Kao RR, Gravenor MB, Charleston B, Hope JC, Martin M, Howard CJ (2007) Mycobacterium bovis shedding patterns from experimentally infected calves and the effect of concurrent infection with bovine viral diarrhoea virus. *J R Soc Interface* 4:545–551
- Kashino SS, Napolitano DR, Skobe Z, Campos-Neto A (2008) Guinea pig model of mycobacterium tuberculosis latent/dormant infection. *Microbes Infect* 10:1469–1476
- Kaur G, Das DK, Singh S, Khan J, Sajid M, Bashir H et al (2019) Tuberculosis vaccine: past experiences and future prospects. In: Hasnain SE, Ehtesham NZ, Grover S (eds) *Mycobacterium tuberculosis: molecular infection biology, pathogenesis, diagnostics and new interventions*. Springer, Singapore, pp 463–495
- Keiser TL, Purdy GE (2017) Killing mycobacterium tuberculosis in vitro: what model systems can teach us. *Microbiol Spectr* 5:28
- Kelley CL, Collins FM (1999) Growth of a highly virulent strain of mycobacterium tuberculosis in mice of differing susceptibility to tuberculous challenge. *Tuber Lung Dis* 79:367–370
- Kelly BP, Furney SK, Jessen MT, Orme IM (1996) Low-dose aerosol infection model for testing drugs for efficacy against mycobacterium tuberculosis. *Antimicrob Agents Chemother* 40: 2809–2812
- Kenyon A, Gavriouchkina D, Zorman J, Napolitani G, Cerundolo V, Sauka-Spengler T (2017) Active nuclear transcriptome analysis reveals inflammasome-dependent mechanism for early neutrophil response to mycobacterium marinum. *Sci Rep* 7:6505
- Kerr EG (1946) Survey of the efficiency of cultures and guinea pig inoculations in the diagnosis of tuberculosis. *Bull Phila Pa Hosp Ayer Clin Lab* 3:447–457
- Kesavan AK, Brooks M, Tufariello J, Chan J, Manabe YC (2009) Tuberculosis genes expressed during persistence and reactivation in the resistant rabbit model. *Tuberculosis* 89:17–21



- Kharatmal S, Jhamb SS, Singh PP (2009) Evaluation of bactec 460 tb system for rapid in vitro screening of drugs against latent state mycobacterium tuberculosis h37rv under hypoxia conditions. *J Microbiol Methods* 78:161–164
- Khare G, Nangpal P, Tyagi AK (2019) Challenges and advances in tb drug discovery. In: Hasnain SE, Ehtesham NZ, Grover S (eds) *Mycobacterium tuberculosis: molecular infection biology, pathogenesis, diagnostics and new interventions*. Springer, Singapore, pp 463–495
- Kjellsson MC, Via LE, Goh A, Weiner D, Low KM, Kern S et al (2012) Pharmacokinetic evaluation of the penetration of antituberculosis agents in rabbit pulmonary lesions. *Antimicrob Agents Chemother* 56:446–457
- Klinkenberg LG, Sutherland LA, Bishai WR, Karakousis PC (2008) Metronidazole lacks activity against mycobacterium tuberculosis in an in vivo hypoxic granuloma model of latency. *J Infect Dis* 198:275–283
- Klopprogge F, Hammond R, Kipper K, Gillespie SH, Della Pasqua O (2019) Mimicking in-vivo exposures to drug combinations in-vitro: anti-tuberculosis drugs in lung lesions and the hollow fiber model of infection. *Sci Rep* 9:13228
- Knezevic AL, McNulty WP (1967) Tuberculosis in lemur mongoz. *Folia Primatol* 6:153–159
- Kolonko M, Geffken AC, Blumer T, Hagens K, Schaible UE, Hagedorn M (2014) Wash-driven actin polymerization is required for efficient mycobacterial phagosome maturation arrest. *Cell Microbiol* 16:232–246
- Kramnik I (2008) Genetic dissection of host resistance to mycobacterium tuberculosis: the sst1 locus and the ipr1 gene. *Curr Top Microbiol Immunol* 321:123–148
- Kumar N, Vishwas KG, Kumar M, Reddy J, Parab M, Manikanth CL et al (2014) Pharmacokinetics and dose response of anti-tb drugs in rat infection model of tuberculosis. *Tuberculosis* 94:282–286
- Kunnath-Velayudhan S, Davidow AL, Wang HY, Molina DM, Huynh VT, Salamon H et al (2012) Proteome-scale antibody responses and outcome of mycobacterium tuberculosis infection in nonhuman primates and in tuberculosis patients. *J Infect Dis* 206:697–705
- Kupz A, Zedler U, Staber M, Kaufmann SH (2016) A mouse model of latent tuberculosis infection to study intervention strategies to prevent reactivation. *PLoS One* 11:e0158849
- Kuroda MJ, Sugimoto C, Cai Y, Merino KM, Mehra S, Arainga M et al (2018) High turnover of tissue macrophages contributes to tuberculosis reactivation in simian immunodeficiency virus-infected rhesus macaques. *J Infect Dis* 217:1865–1874
- Kurtz SL, Rossi AP, Beamer GL, Gatti DM, Kramnik I, Elkins KL (2020) The diversity outbred mouse population is an improved animal model of vaccination against tuberculosis that reflects heterogeneity of protection. *mSphere* 5:e00097
- Kwan PKW, Lin W, Naim ANM, Periaswamy B, De Sessions PF, Hibberd ML et al (2020) Gene expression responses to anti-tuberculous drugs in a whole blood model. *BMC Microbiol* 20:81
- Langermans JA, Andersen P, van Soolingen D, Vervenne RA, Frost PA, van der Laan T et al (2001) Divergent effect of bacillus calmette-guerin (bcg) vaccination on mycobacterium tuberculosis infection in highly related macaque species: implications for primate models in tuberculosis vaccine research. *Proc Natl Acad Sci U S A* 98:11497–11502
- Latt RH (1975) Runyon group III atypical mycobacteria as a cause of tuberculosis in a rhesus monkey. *Lab Anim Sci* 25:206–209
- Lau DT, Fuller JM, Sumner PE (1972) Tuberculosis in a pig-tailed macaque. *J Am Vet Med Assoc* 161:696–699
- Leathers CW, Hamm TE Jr (1976) Naturally occurring tuberculosis in a squirrel monkey and a cebus monkey. *J Am Vet Med Assoc* 169:909–911
- Lecoeur HF, Lagrange PH, Truffot-Pernot C, Gheorghiu M, Grosset J (1989) Relapses after stopping chemotherapy for experimental tuberculosis in genetically resistant and susceptible strains of mice. *Clin Exp Immunol* 76:458–462
- Lee BY, Clemens DL, Silva A, Dillon BJ, Maslesa-Galic S, Nava S et al (2018) Ultra-rapid near universal tb drug regimen identified via parabolic response surface platform cures mice of both conventional and high susceptibility. *PLoS One* 13:e0207469

- Lerche NW, Yee JL, Capuano SV, Flynn JL (2008) New approaches to tuberculosis surveillance in nonhuman primates. *ILAR J* 49:170–178
- Lesellier S, Corner L, Costello E, Sleeman P, Lyashchenko K, Greenwald R et al (2008) Antigen specific immunological responses of badgers (meles meles) experimentally infected with mycobacterium bovis. *Vet Immunol Immunopathol* 122:35–45
- Lewinsohn DM, Tydeman IS, Frieder M, Grotzke JE, Lines RA, Ahmed S et al (2006) High resolution radiographic and fine immunologic definition of tb disease progression in the rhesus macaque. *Microbes Infect* 8:2587–2598
- Lewis PA, Margot AG (1914) The function of the spleen in the experimental infection of albino mice with bacillus tuberculosis. *J Exp Med* 19:187–194
- Li X, Grossman CJ, Mendenhall CL, Hurtubise P, Rouster SD, Roselle GA et al (1998) Host response to mycobacterial infection in the alcoholic rat: male and female dimorphism. *Alcohol* 16:207–212
- Li YL, Chen BW, Xu M, Luo YA, Wang GZ, Shen XB et al (2010) A guinea pig model of latent mycobacterium tuberculosis h37rv infection. *Zhonghua Jie He He Hu Xi Za Zhi* 33:684–687
- Li Z, Liu H, Li H, Dang G, Cui Z, Song N et al (2019) Pe17 protein from mycobacterium tuberculosis enhances mycobacterium smegmatis survival in macrophages and pathogenicity in mice. *Microb Pathog* 126:63–73
- Li J, Zhao A, Tang J, Wang G, Shi Y, Zhan L et al (2020) Tuberculosis vaccine development: From classic to clinical candidates. *Eur J Clin Microbiol Infect Dis* 39:1405–1425
- Lienard J, Carlsson F (2017) Murine mycobacterium marinum infection as a model for tuberculosis. *Methods Mol Biol* 1535:301–315
- Lin PL, Pawar S, Myers A, Pegu A, Fuhrman C, Reinhart TA et al (2006) Early events in mycobacterium tuberculosis infection in cynomolgus macaques. *Infect Immun* 74:3790–3803
- Lin PL, Rodgers M, Smith L, Bigbee M, Myers A, Bigbee C et al (2009) Quantitative comparison of active and latent tuberculosis in the cynomolgus macaque model. *Infect Immun* 77:4631–4642
- Lin PL, Maiello P, Gideon HP, Coleman MT, Cadena AM, Rodgers MA et al (2016) Pet ct identifies reactivation risk in cynomolgus macaques with latent *M. tuberculosis*. *PLoS Pathog* 12:e1005739
- Lindsey JR, Melby EC Jr (1966) Naturally occurring primary cutaneous tuberculosis in the rhesus monkey. *Lab Anim Care* 16:369–385
- Lithander A (1957) A comparison between concentrations and guinea-pig tests in the bacteriological diagnosis of tuberculosis in sputum. *Acta Pathol Microbiol Scand* 40:61–66
- Liu L, Fu R, Yuan X, Shi C, Wang S, Lu X et al (2015a) Differential immune responses and protective effects in avirulent mycobacterial strains vaccinated balb/c mice. *Curr Microbiol* 71:129–135
- Liu X, Jia W, Wang H, Wang Y, Ma J, Wang H et al (2015b) Establishment of a rabbit model of spinal tuberculosis using mycobacterium tuberculosis strain h37rv. *Jpn J Infect Dis* 68:89–97
- Logan KE, Gavier-Widen D, Hewinson RG, Hogarth PJ (2008) Development of a mycobacterium bovis intranasal challenge model in mice. *Tuberculosis* 88:437–443
- Lopez Hernandez Y, Yero D, Pinos-Rodriguez JM, Gibert I (2015) Animals devoid of pulmonary system as infection models in the study of lung bacterial pathogens. *Front Microbiol* 6:38
- Lopez V, Villar M, Queiros J, Vicente J, Mateos-Hernandez L, Diez-Delgado I et al (2016) Comparative proteomics identifies host immune system proteins affected by infection with mycobacterium bovis. *PLoS Negl Trop Dis* 10:e0004541
- Lopez V, Rivalde MA, Contreras M, Mateos-Hernandez L, Vicente J, Gortazar C et al (2018) Heat-inactivated mycobacterium bovis protects zebrafish against mycobacteriosis. *J Fish Dis* 41:1515–1528
- Luo Q, Mehra S, Golden NA, Kaushal D, Lacey MR (2014) Identification of biomarkers for tuberculosis susceptibility via integrated analysis of gene expression and longitudinal clinical data. *Front Genet* 5:240

- Luukinen H, Hammaren MM, Vanha-Aho LM, Parikka M (2018) Modeling tuberculosis in mycobacterium marinum infected adult zebrafish. *J Vis Exp* 140:58299
- Ly LH, Barhoumi R, Cho SH, Franzblau SG, McMurray DN (2008) Vaccination with bacille-calmette guerin promotes mycobacterial control in guinea pig macrophages infected in vivo. *J Infect Dis* 198:768–771
- Lyadova I, Yeremeev V, Majorov K, Nikonenko B, Khaidukov S, Kondratieva T et al (1998) An ex vivo study of t lymphocytes recovered from the lungs of i/st mice infected with and susceptible to mycobacterium tuberculosis. *Infect Immun* 66:4981–4988
- Lynch CJ, Pierce-Chase CH, Dubos R (1965) A genetic study of susceptibility to experimental tuberculosis in mice infected with mammalian tubercle bacilli. *J Exp Med* 121:1051–1070
- MacGilvary NJ, Kevorkian YL, Tan S (2019) Potassium response and homeostasis in mycobacterium tuberculosis modulates environmental adaptation and is important for host colonization. *PLoS Pathog* 15:e1007591
- Machotka SV, Chapple FE, Stookey JL (1975) Cerebral tuberculosis in a rhesus monkey. *J Am Vet Med Assoc* 167:648–650
- Mackintosh CG, Qureshi T, Waldrup K, Labes RE, Dodds KG, Griffin JF (2000) Genetic resistance to experimental infection with mycobacterium bovis in red deer (cervus elaphus). *Infect Immun* 68:1620–1625
- Mahoney A, Weetjens BJ, Cox C, Beyene N, Reither K, Makingi G et al (2012) Pouched rats' detection of tuberculosis in human sputum: comparison to culturing and polymerase chain reaction. *Tuberc Res Treat* 2012:716989
- Maiello P, DiFazio RM, Cadena AM, Rodgers MA, Lin PL, Scanga CA et al (2018) Rhesus macaques are more susceptible to progressive tuberculosis than cynomolgus macaques: a quantitative comparison. *Infect Immun* 86:e00505
- Manabe YC, Dannenberg AM Jr, Tyagi SK, Hatem CL, Yoder M, Woolwine SC et al (2003) Different strains of mycobacterium tuberculosis cause various spectrums of disease in the rabbit model of tuberculosis. *Infect Immun* 71:6004–6011
- Manabe YC, Kesavan AK, Lopez-Molina J, Hatem CL, Brooks M, Fujiwara R et al (2008) The aerosol rabbit model of tb latency, reactivation and immune reconstitution inflammatory syndrome. *Tuberculosis* 88:187–196
- Marino S, Kirschner DE (2016) A multi-compartment hybrid computational model predicts key roles for dendritic cells in tuberculosis infection. *Computation* 4:39
- Marino S, Pawar S, Fuller CL, Reinhart TA, Flynn JL, Kirschner DE (2004) Dendritic cell trafficking and antigen presentation in the human immune response to mycobacterium tuberculosis. *J Immunol* 173:494–506
- Marino S, Cilfone NA, Mattila JT, Linderman JJ, Flynn JL, Kirschner DE (2015) Macrophage polarization drives granuloma outcome during mycobacterium tuberculosis infection. *Infect Immun* 83:324–338
- Marino S, Gideon HP, Gong C, Mankad S, McCrone JT, Lin PL et al (2016) Computational and empirical studies predict mycobacterium tuberculosis-specific t cells as a biomarker for infection outcome. *PLoS Comput Biol* 12:e1004804
- Markova N, Michailova L, Kussovski V, Jourdanova M, Radoucheva T (2005) Intranasal application of lentinan enhances bactericidal activity of rat alveolar macrophages against mycobacterium tuberculosis. *Pharmazie* 60:42–48
- Martens GW, Arikan MC, Lee J, Ren F, Greiner D, Kornfeld H (2007) Tuberculosis susceptibility of diabetic mice. *Am J Respir Cell Mol Biol* 37:518–524
- Martin AR (1946) The use of mice in the examination of drugs for chemotherapeutic activity against mycobacterium tuberculosis. *J Pathol Bacteriol* 58:580–585
- Martin JE, Cole WC, Whitney RA Jr (1968) Tuberculosis of the spine (pott's disease) in a rhesus monkey (macaca mulatta). *J Am Vet Med Assoc* 153:914–917
- Martin T, Cheke D, Natyshak I (1989) Broth culture: The modern 'guinea-pig' for isolation of mycobacteria. *Tubercle* 70:53–56

- Martin A, Takiff H, Vandamme P, Swings J, Palomino JC, Portaels F (2006) A new rapid and simple colorimetric method to detect pyrazinamide resistance in mycobacterium tuberculosis using nicotinamide. *J Antimicrob Chemother* 58:327–331
- Martin CJ, Cadena AM, Leung VW, Lin PL, Maiello P, Hicks N et al (2017) Digitally barcoding mycobacterium tuberculosis reveals in vivo infection dynamics in the macaque model of tuberculosis. *MBio* 8:e00312
- Martino M, Hubbard GB, Schlabritz-Loutsevitch N (2007) Tuberculosis (mycobacterium tuberculosis) in a pregnant baboon (papio cynocephalus). *J Med Primatol* 36:108–112
- Mattila JT, Ojo OO, Kepka-Lenhart D, Marino S, Kim JH, Eum SY et al (2013) Microenvironments in tuberculous granulomas are delineated by distinct populations of macrophage subsets and expression of nitric oxide synthase and arginase isoforms. *J Immunol* 191:773–784
- Mattila JT, Beaino W, Maiello P, Coleman MT, White AG, Scanga CA et al (2017) Positron emission tomography imaging of macaques with tuberculosis identifies temporal changes in granuloma glucose metabolism and integrin alpha4beta1-expressing immune cells. *J Immunol* 199:806–815
- Mc CA, Katsampes CP, Clausen SW (1946) Effects of intranasal inoculation with tubercle bacilli on vitamin stores and tissues of mice and rats. *Am Rev Tuberc* 54:84–91
- McCallan L, Corbett D, Andersen PL, Aagaard C, McMurray D, Barry C et al (2011) A new experimental infection model in ferrets based on aerosolised mycobacterium bovis. *Vet Med Int* 2011:981410
- McFarland CT, Ly L, Jeevan A, Yamamoto T, Weeks B, Izzo A et al (2010) Bcg vaccination in the cotton rat (*sigmodon hispidus*) infected by the pulmonary route with virulent mycobacterium tuberculosis. *Tuberculosis* 90:262–267
- McFarlane AJ, McSorley HJ, Davidson DJ, Fitch PM, Errington C, Mackenzie KJ et al (2017) Enteric helminth-induced type I interferon signaling protects against pulmonary virus infection through interaction with the microbiota. *J Allergy Clin Immunol* 140:1068–1078
- McMurray DN (2003) Hematogenous reseeding of the lung in low-dose, aerosol-infected guinea pigs: Unique features of the host-pathogen interface in secondary tubercles. *Tuberculosis* 83:131–134
- Medina E, North RJ (1998) Resistance ranking of some common inbred mouse strains to mycobacterium tuberculosis and relationship to major histocompatibility complex haplotype and nramp1 genotype. *Immunology* 93:270–274
- Mehra S, Pahar B, Dutta NK, Conerly CN, Philippi-Falkenstein K, Alvarez X et al (2010) Transcriptional reprogramming in nonhuman primate (rhesus macaque) tuberculosis granulomas. *PLoS One* 5:e12266
- Meinzen C, Proano A, Gilman RH, Caviedes L, Coronel J, Zimic M et al (2016) A quantitative adaptation of the wayne test for pyrazinamide resistance. *Tuberculosis* 99:41–46
- Mendoza-Coronel E, Castanon-Arreola M (2016) Comparative evaluation of in vitro human macrophage models for mycobacterial infection study. *Pathog Dis* 74:52
- Merrick JV, Ratcliffe HL (1957) Tuberculosis induced by droplet nuclei infection; its developmental pattern in hamsters in relation to levels of dietary protein. *Am J Pathol* 33:107–129
- Mgode GF, Weetjens BJ, Nawrath T, Cox C, Jubitana M, Machang'u RS et al (2012) Diagnosis of tuberculosis by trained african giant pouched rats and confounding impact of pathogens and microflora of the respiratory tract. *J Clin Microbiol* 50:274–280
- Michael M Jr, Cummings MM, Bloom WL (1950) Course of experimental tuberculosis in the albino rat as influenced by cortisone. *Proc Soc Exp Biol Med* 75:613–616
- Miller HE, Johnson KE, Tarakanova VL, Robinson RT (2019) Gamma-herpesvirus latency attenuates mycobacterium tuberculosis infection in mice. *Tuberculosis* 116:56–60
- Min F, He L, Luo Y, Huang S, Pan J, Wang J et al (2018) Dynamics of immune responses during experimental mycobacterium kansasii infection of cynomolgus monkeys (*macaca fascicularis*). *Mediat Inflamm* 2018:8354902
- Mishra AK, Yabaji SM, Dubey RK (2018) Evaluation of isoprinosine to be repurposed as an adjunct anti-tuberculosis chemotherapy. *Med Hypotheses* 115:77–80

- Mitchison DA, Allen BW, Lambert RA (1973) Selective media in the isolation of tubercle bacilli from tissues. *J Clin Pathol* 26:250–252
- Monin L, Griffiths KL, Lam WY, Gopal R, Kang DD, Ahmed M et al (2015) Helminth-induced arginase-1 exacerbates lung inflammation and disease severity in tuberculosis. *J Clin Invest* 125: 4699–4713
- Moreira-Teixeira L, Stimpson PJ, Stavropoulos E, Hadebe S, Chakravarty P, Ioannou M et al (2020) Type I IFN exacerbates disease in tuberculosis-susceptible mice by inducing neutrophil-mediated lung inflammation and netosis. *Nat Commun* 11:5566
- Morton JJ (1916) A rapid method for the diagnosis of renal tuberculosis by the use of the X-rayed guinea pig. *J Exp Med* 24:419–427
- Mourik BC, Leenen PJ, de Kneegt GJ, Huizinga R, van der Eerden BC, Wang J et al (2017) Immunotherapy added to antibiotic treatment reduces relapse of disease in a mouse model of tuberculosis. *Am J Respir Cell Mol Biol* 56:233–241
- Mueller AK, Behrends J, Hagens K, Mahlo J, Schaible UE, Schneider BE (2012) Natural transmission of *Plasmodium berghei* exacerbates chronic tuberculosis in an experimental co-infection model. *PLoS One* 7:e48110
- Mueller AK, Behrends J, Blank J, Schaible UE, Schneider BE (2014) An experimental model to study tuberculosis-malaria coinfection upon natural transmission of *Mycobacterium tuberculosis* and *Plasmodium berghei*. *J Vis Exp* 84:e50829
- Mulder C, Mgode GF, Ellis H, Valverde E, Beyene N, Cox C et al (2017) Accuracy of giant African pouched rats for diagnosing tuberculosis: comparison with culture and *xpert(®)* *mtb/rif*. *Int J Tuberc Lung Dis* 21:1127–1133
- Murphy JB, Ellis AW (1914) Experiments on the role of lymphoid tissue in the resistance to experimental tuberculosis in mice. *J Exp Med* 20:397–403
- Myllymaki H, Bauerlein CA, Ramet M (2016) The zebrafish breathes new life into the study of tuberculosis. *Front Immunol* 7:196
- Naranjo V, Ayoubi P, Vicente J, Ruiz-Fons F, Gortazar C, Kocan KM et al (2006) Characterization of selected genes upregulated in non-tuberculous European wild boar as possible correlates of resistance to *Mycobacterium bovis* infection. *Vet Microbiol* 116:224–231
- Narayanan RB, Badenoch-Jones P, Turk JL (1981) Experimental mycobacterial granulomas in guinea pig lymph nodes: ultrastructural observations. *J Pathol* 134:253–265
- Nedelchev GG, Raghunand TR, Jassal MS, Lun S, Cheng QJ, Bishai WR (2009) Extrapulmonary dissemination of *Mycobacterium bovis* but not *Mycobacterium tuberculosis* in a bronchoscopic rabbit model of cavitary tuberculosis. *Infect Immun* 77:598–603
- Negre L, Bretey J (1945) Influence exerted on guinea pig tuberculosis by the BGG administered by cutaneous scarification. *Ann Inst Pasteur* 71:161–167
- Newton S, Martineau A, Kampmann B (2011) A functional whole blood assay to measure viability of mycobacteria, using reporter-gene tagged *BCG* or *M. Tb* (*bcglux/m. Tb lux*). *J Vis Exp* 55:3332
- Neyrolles O, Hernandez-Pando R, Pietri-Rouxel F, Fornes P, Tailleux L, Barrios Payan JA et al (2006) Is adipose tissue a place for *Mycobacterium tuberculosis* persistence? *PLoS One* 1:e43
- Niazi MK, Dhulekar N, Schmidt D, Major S, Cooper R, Abeijon C et al (2015) Lung necrosis and neutrophils reflect common pathways of susceptibility to *Mycobacterium tuberculosis* in genetically diverse, immune-competent mice. *Dis Model Mech* 8:1141–1153
- Nie WJ, Xie ZY, Gao S, Teng TL, Zhou WQ, Shang YY et al (2020) Efficacy of moxifloxacin against *Mycobacterium abscessus* in zebrafish model in vivo. *Biomed Environ Sci* 33:350–358
- Nikonenko BV, Averbakh MM, Lavebratt C, Schurr E, Apt AS (2000) Comparative analysis of mycobacterial infections in susceptible *i/st* and resistant *a/sn* inbred mice. *Tuber Lung Dis* 80: 15–25
- Noll KE, Ferris MT, Heise MT (2019) The collaborative cross: a systems genetics resource for studying host-pathogen interactions. *Cell Host Microbe* 25:484–498
- Nugent G, Whitford EJ, Yockney I, Perry M, Tompkins DM, Holtslag N et al (2013a) Percutaneous interdigital injection of *Mycobacterium bovis* as a model for tuberculous lesion development in wild brushtail possums (*Trichosurus vulpecula*). *J Comp Pathol* 148:33–42

- Nugent G, Yockney I, Whitford J, Cross ML (2013b) Mortality rate and gross pathology due to tuberculosis in wild brushtail possums (*Trichosurus vulpecula*) following low dose subcutaneous injection of mycobacterium bovis. *Prev Vet Med* 109:168–175
- Nugent G, Buddle BM, Knowles G (2015) Epidemiology and control of mycobacterium bovis infection in brushtail possums (*Trichosurus vulpecula*), the primary wildlife host of bovine tuberculosis in New Zealand. *N Z Vet J* 63(Suppl 1):28–41
- Nusbaum RJ, Calderon VE, Huante MB, Sutjita P, Vijayakumar S, Lancaster KL et al (2016) Pulmonary tuberculosis in humanized mice infected with HIV-1. *Sci Rep* 6:21522
- O'Brien P, Vinnard C, Subbian S (2020) An improved protocol to establish experimental tuberculous meningitis in the rabbit. *MethodsX* 7:100832
- Oehlers SH, Hortle E, Cook KM (2020) A zebrafish model of tuberculosis comorbidity and the effects of hIF-1 $\alpha$  activating intervention. *FEBS J* 287:3917–3920
- Oh CT, Moon C, Choi TH, Kim BS, Jang J (2013) Mycobacterium marinum infection in *Drosophila melanogaster* for antimycobacterial activity assessment. *J Antimicrob Chemother* 68:601–609
- Oksanen KE, Halfpenny NJ, Sherwood E, Harjula SK, Hammaren MM, Ahava MJ et al (2013) An adult zebrafish model for preclinical tuberculosis vaccine development. *Vaccine* 31:5202–5209
- Ordway D, Palanisamy G, Henao-Tamayo M, Smith EE, Shanley C, Orme IM et al (2007) The cellular immune response to mycobacterium tuberculosis infection in the guinea pig. *J Immunol* 179:2532–2541
- Ozeki Y, Tsutsui H, Kawada N, Suzuki H, Kataoka M, Kodama T et al (2006) Macrophage scavenger receptor down-regulates mycobacterial cord factor-induced proinflammatory cytokine production by alveolar and hepatic macrophages. *Microb Pathog* 40:171–176
- Pacheco SA, Powers KM, Engelmann F, Messaoudi I, Purdy GE (2013) Autophagic killing effects against mycobacterium tuberculosis by alveolar macrophages from young and aged rhesus macaques. *PLoS One* 8:e66985
- Palanisamy GS, Smith EE, Shanley CA, Ordway DJ, Orme IM, Basaraba RJ (2008) Disseminated disease severity as a measure of virulence of mycobacterium tuberculosis in the guinea pig model. *Tuberculosis* 88:295–306
- Palermo-Neto J, Santos FA, Guerra JL, Santos GO, Pinheiro SR (2001) Glue solvent inhalation impairs host resistance to mycobacterium bovis-induced infection in hamsters. *Vet Hum Toxicol* 43:1–5
- Palmer MV, Whipple DL, Olsen SC (1999) Development of a model of natural infection with mycobacterium bovis in white-tailed deer. *J Wildl Dis* 35:450–457
- Palmer MV, Waters WR, Whipple DL (2002) Aerosol delivery of virulent mycobacterium bovis to cattle. *Tuberculosis* 82:275–282
- Palmer MV, Thacker TC, Waters WR, Gortazar C, Corner LA (2012) Mycobacterium bovis: a model pathogen at the interface of livestock, wildlife, and humans. *Vet Med Int* 2012:236205
- Palucci I, Battah B, Salustri A, De Maio F, Petrone L, Ciccocanti F et al (2019) Ip-10 contributes to the inhibition of mycobacterial growth in an ex vivo whole blood assay. *Int J Med Microbiol* 309:299–306
- Pardieu C, Casali N, Clark SO, Hooper R, Williams A, Velji P et al (2015) Correlates between models of virulence for mycobacterium tuberculosis among isolates of the central Asian lineage: a case for lysozyme resistance testing? *Infect Immun* 83:2213–2223
- Parikka M, Hammaren MM, Harjula SK, Halfpenny NJ, Oksanen KE, Lahtinen MJ et al (2012) Mycobacterium marinum causes a latent infection that can be reactivated by gamma irradiation in adult zebrafish. *PLoS Pathog* 8:e1002944
- Parish T (2020) In vitro drug discovery models for mycobacterium tuberculosis relevant for host infection. *Expert Opin Drug Discovery* 15:349–358
- Parsons SD, de Villiers C, Gey NC, van Pittius, Warren RM, van Helden PD (2010) Detection of mycobacterium kansasii infection in a rhesus macaque (*Macaca mulatta*) using a modified quantiferon-tb gold assay. *Vet Immunol Immunopathol* 136:330–334
- Pasipanodya JG, Nuernberger E, Romero K, Hanna D, Gumbo T (2015) Systematic analysis of hollow fiber model of tuberculosis experiments. *Clin Infect Dis* 61(Suppl 1):S10–S17

- Patel K, Jhamb SS, Singh PP (2011) Models of latent tuberculosis: their salient features, limitations, and development. *J Lab Phys* 3:75–79
- Pathak S, Awuh JA, Leversen NA, Flo TH, Asjo B (2012) Counting mycobacteria in infected human cells and mouse tissue: a comparison between qpcr and cfu. *PLoS One* 7:e34931
- Pelaez Coyotl EA, Barrios Palacios J, Mucino G, Moreno-Blas D, Costas M, Montiel Montes T et al (2020) Antimicrobial peptide against mycobacterium tuberculosis that activates autophagy is an effective treatment for tuberculosis. *Pharmaceutics* 12:1071
- Pena JC, Ho WZ (2016) Non-human primate models of tuberculosis. *Microbiol Spectr* 4:4
- Phalen SW, McMurray DN (1993) T-lymphocyte response in a guinea pig model of tuberculous pleuritis. *Infect Immun* 61:142–145
- Pi J, Shen L, Shen H, Yang E, Wang W, Wang R et al (2019) Mannosylated graphene oxide as macrophage-targeted delivery system for enhanced intracellular m.Tuberculosis killing efficiency. *Mater Sci Eng C Mater Biol Appl* 103:109777
- Pienaar E, Matern WM, Linderman JJ, Bader JS, Kirschner DE (2016) Multiscale model of mycobacterium tuberculosis infection maps metabolite and gene perturbations to granuloma sterilization predictions. *Infect Immun* 84:1650–1669
- Pienaar E, Sarathy J, Prideaux B, Dietzold J, Dartois V, Kirschner DE et al (2017) Comparing efficacies of moxifloxacin, levofloxacin and gatifloxacin in tuberculosis granulomas using a multi-scale systems pharmacology approach. *PLoS Comput Biol* 13:e1005650
- Pierce C, Dubos RJ, Middlebrook G (1947) Infection of mice with mammalian tubercle bacilli grown in tween-albumin liquid medium. *J Exp Med* 86:159–174
- Pieterman ED, Te Brake LHM, de Knegt GJ, van der Meijden A, Alffenaar JC, Bax HI et al (2018) Assessment of the additional value of verapamil to a moxifloxacin and linezolid combination regimen in a murine tuberculosis model. *Antimicrob Agents Chemother* 62:e00312
- Pieterman ED, van den Berg S, van der Meijden A, Svensson EM, Bax HI, de Steenwinkel JEM (2021) Higher dosing of rifamycins does not increase activity against M. tuberculosis in the hollow fibre infection model. *Antimicrob Agents Chemother* 65(4):e02255
- Plesker R, Teschner K, Behlert O, Prenger-Berninghoff E, Hillemann D (2010) Airborne mycobacterium avium infection in a group of red-shanked douc langurs (*pygathrix nemaeus nemaeus*). *J Med Primatol* 39:129–135
- Podell BK, Ackart DF, Obregon-Henao A, Eck SP, Henao-Tamayo M, Richardson M et al (2014) Increased severity of tuberculosis in guinea pigs with type 2 diabetes: a model of diabetes-tuberculosis comorbidity. *Am J Pathol* 184:1104–1118
- Popovic M, Yaparla A, Paquin-Proulx D, Koubourli DV, Webb R, Firmani M et al (2019) Colony-stimulating factor-1- and interleukin-34-derived macrophages differ in their susceptibility to mycobacterium marinum. *J Leukoc Biol* 106:1257–1269
- Potter EL, Gideon HP, Tkachev V, Fabozzi G, Chassiakos A, Petrovas C et al (2021) Measurement of leukocyte trafficking kinetics in macaques by serial intravascular staining. *Sci Transl Med* 13:4582
- Prouty MG, Correa NE, Barker LP, Jagadeeswaran P, Klose KE (2003) Zebrafish-mycobacterium marinum model for mycobacterial pathogenesis. *FEMS Microbiol Lett* 225:177–182
- Pushkaran AC, Vinod V, Vanuopadath M, Nair SS, Nair SV, Vasudevan AK et al (2019) Combination of repurposed drug diosmin with amoxicillin-clavulanic acid causes synergistic inhibition of mycobacterial growth. *Sci Rep* 9:6800
- Queiros J, Vicente J (2018) Inbreeding shapes tuberculosis progression in female adult badgers (meles meles). *J Anim Ecol* 87:1497–1499
- Rafi W, Bhatt K, Gause WC, Salgame P (2015) Neither primary nor memory immunity to mycobacterium tuberculosis infection is compromised in mice with chronic enteric helminth infection. *Infect Immun* 83:1217–1223
- Rahim Z, Thapa J, Fukushima Y, van der Zanden AGM, Gordon SV, Suzuki Y et al (2017) Tuberculosis caused by mycobacterium orygis in dairy cattle and captured monkeys in bangladesh: A new scenario of tuberculosis in south asia. *Transbound Emerg Dis* 64:1965–1969

- Ramakrishnan L, Falkow S (1994) *Mycobacterium marinum* persists in cultured mammalian cells in a temperature-restricted fashion. *Infect Immun* 62:3222–3229
- Ramakrishnan L, Valdivia RH, McKerrow JH, Falkow S (1997) *Mycobacterium marinum* causes both long-term subclinical infection and acute disease in the leopard frog (*Rana pipiens*). *Infect Immun* 65:767–773
- Ramos L, Obregon-Henao A, Henao-Tamayo M, Bowen R, Lunney JK, Gonzalez-Juarrero M (2017) The minipig as an animal model to study *Mycobacterium tuberculosis* infection and natural transmission. *Tuberculosis* 106:91–98
- Rao Muvva J, Ahmed S, Rekha RS, Kalsum S, Groenheit R, Schon T et al (2021) Immunomodulatory agents combat multidrug-resistant tuberculosis by improving antimicrobial immunity. *J Infect Dis* 224:332–344
- Rao NA, Albini TA, Kumaradas M, Pinn ML, Fraig MM, Karakousis PC (2009) Experimental ocular tuberculosis in guinea pigs. *Arch Ophthalmol* 127:1162–1166
- Raposo-Garcia S, Guerra-Laso JM, Garcia-Garcia S, Juan-Garcia J, Lopez-Fidalgo E, Diez-Tascon C et al (2017) Immunological response to *Mycobacterium tuberculosis* infection in blood from type 2 diabetes patients. *Immunol Lett* 186:41–45
- Ratcliffe HL, Palladino VS (1953) Tuberculosis induced by droplet nuclei infection; initial homogeneous response of small mammals (rats, mice, guinea pigs, and hamsters) to human and to bovine bacilli, and the rate and pattern of tubercle development. *J Exp Med* 97:61–68
- Rayner EL, Pearson GR, Hall GA, Basaraba RJ, Gleeson F, McIntyre A et al (2013) Early lesions following aerosol infection of rhesus macaques (*Macaca mulatta*) with *Mycobacterium tuberculosis* strain H37rv. *J Comp Pathol* 149:475–485
- Redford PS, Mayer-Barber KD, McNab FW, Stavropoulos E, Wack A, Sher A et al (2014) Influenza A virus impairs control of *Mycobacterium tuberculosis* coinfection through a type I interferon receptor-dependent pathway. *J Infect Dis* 209:270–274
- Reece ST, Loddenkemper C, Askew DJ, Zedler U, Schommer-Leitner S, Stein M et al (2010) Serine protease activity contributes to control of *Mycobacterium tuberculosis* in hypoxic lung granulomas in mice. *J Clin Invest* 120:3365–3376
- Reis AC, Ramos B, Pereira AC, Cunha MV (2020) The hard numbers of tuberculosis epidemiology in wildlife: a meta-regression and systematic review. *Transbound Emerg Dis* 68(6):3257–3276
- Renner M, Bartholomew WR (1974) Mycobacteriologic data from two outbreaks of bovine tuberculosis in nonhuman primates. *Am Rev Respir Dis* 109:11–16
- Rhoo KH, Edholm ES, Forzan MJ, Khan A, Waddle AW, Pavelka MS Jr et al (2019) Distinct host-mycobacterial pathogen interactions between resistant adult and tolerant tadpole life stages of *Xenopus laevis*. *J Immunol* 203:2679–2688
- Rifat D, Bishai WR, Karakousis PC (2009) Phosphate depletion: a novel trigger for *Mycobacterium tuberculosis* persistence. *J Infect Dis* 200:1126–1135
- Rifat D, Prideaux B, Savic RM, Urbanowski ME, Parsons TL, Luna B et al (2018) Pharmacokinetics of rifapentine and rifampin in a rabbit model of tuberculosis and correlation with clinical trial data. *Sci Transl Med* 10:7786
- Righi DA, Pinheiro SR, Guerra JL, Palermo-Neto J (1999) Effects of diazepam on *Mycobacterium bovis*-induced infection in hamsters. *Braz J Med Biol Res* 32:1145–1153
- Ring S, Eggers L, Behrends J, Wutkowski A, Schwudke D, Kroger A et al (2019) Blocking IL-10 receptor signaling ameliorates *Mycobacterium tuberculosis* infection during influenza-induced exacerbation. *JCI Insight* 5:e126533
- Risalde MA, Lopez V, Contreras M, Mateos-Hernandez L, Gortazar C, de la Fuente J (2018) Control of mycobacteriosis in zebrafish (*Danio rerio*) mucosally vaccinated with heat-inactivated *Mycobacterium bovis*. *Vaccine* 36:4447–4453
- Rocha VC, Ikuta CY, Gomes MS, Quaglia F, Matushima ER, Ferreira Neto JS (2011) Isolation of *Mycobacterium tuberculosis* from captive ateles paniscus. *Vector Borne Zoonotic Dis* 11:593–594



- Rodgers JD, Connery NL, McNair J, Welsh MD, Skuce RA, Bryson DG et al (2007) Experimental exposure of cattle to a precise aerosolised challenge of mycobacterium bovis: a novel model to study bovine tuberculosis. *Tuberculosis* 87:405–414
- Rodrigues RF, Zarate-Blades CR, Rios WM, Soares LS, Souza PR, Brandao IT et al (2015) Synergy of chemotherapy and immunotherapy revealed by a genome-scale analysis of murine tuberculosis. *J Antimicrob Chemother* 70:1774–1783
- Rosenbaum M, Mendoza P, Ghersi BM, Wilbur AK, Perez-Brumer A, Cavero Yong N et al (2015) Detection of mycobacterium tuberculosis complex in new world monkeys in peru. *EcoHealth* 12:288–297
- Rouco C, Richardson KS, Buddle BM, French NP, Tompkins DM (2016) Sex difference in the survival rate of wild brushtail possums (*trichosurus vulpecula*) experimentally challenged with bovine tuberculosis. *Res Vet Sci* 107:102–105
- Rozenberg AM, Pisarenko NN (1965) The gold hamster as an experimental model for the study of tuberculosis and antitubercular vaccination. *Zh Mikrobiol Epidemiol Immunobiol* 42:131–136
- Ruley KM, Reimschuessel R, Trucksis M (2002) Goldfish as an animal model system for mycobacterial infection. *Methods Enzymol* 358:29–39
- Safar HA, Mustafa AS, Amoudy HA, El-Hashim A (2020) The effect of adjuvants and delivery systems on th1, th2, th17 and treg cytokine responses in mice immunized with mycobacterium tuberculosis-specific proteins. *PLoS One* 15:e0228381
- Sanchez-Hidalgo A, Obregon-Henao A, Wheat WH, Jackson M, Gonzalez-Juarrero M (2017) Mycobacterium bovis hosted by free-living-amoebae permits their long-term persistence survival outside of host mammalian cells and remain capable of transmitting disease to mice. *Environ Microbiol* 19:4010–4021
- Sapolsky RM, Else JG (1987) Bovine tuberculosis in a wild baboon population: Epidemiological aspects. *J Med Primatol* 16:229–235
- Saralahti AK, Uusi-Makela MIE, Niskanen MT, Ramet M (2020) Integrating fish models in tuberculosis vaccine development. *Dis Model Mech* 13:45716
- Sarathy JP, Via LE, Weiner D, Blanc L, Boshoff H, Eugenin EA et al (2018) Extreme drug tolerance of mycobacterium tuberculosis in caseum. *Antimicrob Agents Chemother* 62:e02266
- Sarathy J, Blanc L, Alvarez-Cabrera N, O'Brien P, Dias-Freedman I, Mina M et al (2019) Fluoroquinolone efficacy against tuberculosis is driven by penetration into lesions and activity against resident bacterial populations. *Antimicrob Agents Chemother* 63:e02516
- Saxena PS, Sharma RK (1982) Value of histopathology, culture and guinea pig inoculation in osteoarticular tuberculosis. *Int Surg* 67:540–542
- Scanga CA, Mohan VP, Joseph H, Yu K, Chan J, Flynn JL (1999) Reactivation of latent tuberculosis: variations on the cornell murine model. *Infect Immun* 67:4531–4538
- Scheid G, Mendheim H (1949) About the simultaneous occurrence of spontaneous tuberculosis and malignant spontaneous tumors in the white laboratory rat. *Tuberkulosearzt* 3:88–91
- Schinkothe J, Kohler H, Liebler-Tenorio EM (2016a) Characterization of tuberculous granulomas in different stages of progression and associated tertiary lymphoid tissue in goats experimentally infected with mycobacterium avium subsp. *Hominissuis*. *Comp Immunol Microbiol Infect Dis* 47:41–51
- Schinkothe J, Mobius P, Kohler H, Liebler-Tenorio EM (2016b) Experimental infection of goats with mycobacterium avium subsp. *Hominissuis*: a model for comparative tuberculosis research. *J Comp Pathol* 155:218–230
- Schroeder CR (1938) Acquired tuberculosis in the primate in laboratories and zoological collections. *Am J Public Health Nations Health* 28:469–475
- Sedgwick C, Parcher J, Durham R (1970) Atypical mycobacterial infection in the pig-tailed macaque (*macaca nemestrina*). *J Am Vet Med Assoc* 157:724–725
- Sershen CL, Plimpton SJ, May EE (2016) Oxygen modulates the effectiveness of granuloma mediated host response to mycobacterium tuberculosis: a multiscale computational biology approach. *Front Cell Infect Microbiol* 6:6

- Sesline DH, Schwartz LW, Osburn BI, Thoen CO, Terrell T, Holmberg C et al (1975) Mycobacterium avium infection in three rhesus monkeys. *J Am Vet Med Assoc* 167:639–645
- Sha S, Shi X, Deng G, Chen L, Xin Y, Ma Y (2017) Mycobacterium tuberculosis rv1987 induces th2 immune responses and enhances mycobacterium smegmatis survival in mice. *Microbiol Res* 197:74–80
- Sha S, Shi Y, Tang Y, Jia L, Han X, Liu Y et al (2021) Mycobacterium tuberculosis rv1987 protein induces m2 polarization of macrophages through activating the pi3k/akt1/mTOR signaling pathway. *Immunol Cell Biol* 99:570–585
- Shakila H, Jayasankar K, Ramanathan VD (1999) The clearance of tubercle bacilli & mycobacterial antigen vis a vis the granuloma in different organs of guinea pigs. *Indian J Med Res* 110:4–10
- Shanley CA, Streicher EM, Warren RM, Victor TC, Orme IM (2013) Characterization of w-beijing isolates of mycobacterium tuberculosis from the western cape. *Vaccine* 31:5934–5939
- Sharpe SA, Eschelbach E, Basaraba RJ, Gleeson F, Hall GA, McIntyre A et al (2009) Determination of lesion volume by MRI and stereology in a macaque model of tuberculosis. *Tuberculosis* 89:405–416
- Sharpe S, White A, Gleeson F, McIntyre A, Smyth D, Clark S et al (2016) Ultra low dose aerosol challenge with mycobacterium tuberculosis leads to divergent outcomes in rhesus and cynomolgus macaques. *Tuberculosis* 96:1–12
- Shkurupy VA, Cherdantseva LA, Kovner AV, Troitskiy AV, Bystrova AV, Starostenko AA (2020) Efficacy of inhalations of antituberculous compositions with different length of experimental therapy course in mice. *Bull Exp Biol Med* 168:743–747
- Sibley L, Dennis M, Sarfas C, White A, Clark S, Gleeson F et al (2016) Route of delivery to the airway influences the distribution of pulmonary disease but not the outcome of mycobacterium tuberculosis infection in rhesus macaques. *Tuberculosis* 96:141–149
- Sibley L, Gooch K, Wareham A, Gray S, Chancellor A, Dowall S et al (2019) Differences in monocyte: lymphocyte ratio and tuberculosis disease progression in genetically distinct populations of macaques. *Sci Rep* 9:3340
- Sichewo PR, Etter EMC, Michel AL (2020) Wildlife-cattle interactions emerge as drivers of bovine tuberculosis in traditionally farmed cattle. *Prev Vet Med* 174:104847
- Singh RP, Jhamb SS, Singh PP (2008) Effects of morphine during mycobacterium tuberculosis h37rv infection in mice. *Life Sci* 82:308–314
- Singh RP, Jhamb SS, Singh PP (2009) Effect of morphine on mycobacterium smegmatis infection in mice and macrophages. *Indian J Microbiol* 49:276–282
- Singhal A, Aliouat M, Herve M, Mathys V, Kiass M, Creusy C et al (2011a) Experimental tuberculosis in the wistar rat: a model for protective immunity and control of infection. *PLoS One* 6:e18632
- Singhal A, Mathys V, Kiass M, Creusy C, Delaire B, Aliouat M et al (2011b) Bcg induces protection against mycobacterium tuberculosis infection in the wistar rat model. *PLoS One* 6:e28082
- Sivangala Thandi R, Radhakrishnan RK, Tripathi D, Paidipally P, Azad AK, Schlesinger LS et al (2020) Ornithine-a urea cycle metabolite enhances autophagy and controls mycobacterium tuberculosis infection. *Nat Commun* 11:3535
- Skinner MA, Yuan S, Prestidge R, Chuk D, Watson JD, Tan PL (1997) Immunization with heat-killed mycobacterium vaccae stimulates cd8+ cytotoxic t cells specific for macrophages infected with mycobacterium tuberculosis. *Infect Immun* 65:4525–4530
- Skinner MA, Keen DL, Parlane NA, Yates GF, Buddle BM (2002) Increased protection against bovine tuberculosis in the brushtail possum (*Trichosurus vulpecula*) when BCG is administered with killed mycobacterium vaccae. *Tuberculosis* 82:15–22
- Smith MI, Mc CW, Emmart EW (1946a) Influence of streptomycin and promin on proliferation of tubercle bacilli in the tissues of albino rat. *Proc Soc Exp Biol Med* 62:157–162
- Smith MI, Mc CW, Emmart EW (1946b) The influence of streptomycin and promin on the proliferation of tubercle bacilli in the tissues of the albino rat. *Fed Proc* 5:204

- Smith EK, Hunt RD, Garcia FG, Fraser CE, Merkal RS, Karlson AG (1973) Avian tuberculosis in monkeys. A unique mycobacterial infection. *Am Rev Respir Dis* 107:469–471
- Smith DW, Balasubramanian V, Wiegshaus E (1991) A guinea pig model of experimental airborne tuberculosis for evaluation of the response to chemotherapy: the effect on bacilli in the initial phase of treatment. *Tubercle* 72:223–231
- Smith CM, Proulx MK, Olive AJ, Laddy D, Mishra BB, Moss C et al (2016) Tuberculosis susceptibility and vaccine protection are independently controlled by host genotype. *MBio* 7: e01516
- Smith CM, Proulx MK, Lai R, Kiritsy MC, Bell TA, Hock P et al (2019) Functionally overlapping variants control tuberculosis susceptibility in collaborative cross mice. *MBio* 10:e02791
- Snyder S, Peace T, Soave O, Lund J (1970) Tuberculosis in an owl monkey (*aotus trivirgatus*). *J Am Vet Med Assoc* 157:712–713
- Sohaskey CD, Voskuil MI (2015) In vitro models that utilize hypoxia to induce non-replicating persistence in mycobacteria. *Methods Mol Biol* 1285:201–213
- Solomon JM, Leung GS, Isberg RR (2003) Intracellular replication of mycobacterium marinum within dictyostelium discoideum: efficient replication in the absence of host coronin. *Infect Immun* 71:3578–3586
- Soltys MA, Jennings AR (1950) The dissemination of tubercle bacilli in experimental tuberculosis in the guinea pig. *Am Rev Tuberc* 61:399–406
- Sommer R, Cole ST (2019) Monitoring tuberculosis drug activity in live animals by near-infrared fluorescence imaging. *Antimicrob Agents Chemother* 63(12):e01280
- Srivastava S, Pasipanodya JG, Ramachandran G, Deshpande D, Shuford S, Crosswell HE et al (2016) A long-term co-perfused disseminated tuberculosis-3d liver hollow fiber model for both drug efficacy and hepatotoxicity in babies. *EBioMedicine* 6:126–138
- Srivastava S, van Zyl J, Cirrincione K, Martin K, Thomas T, Deshpande D et al (2020) Evaluation of ceftriaxone plus avibactam in an intracellular hollow fiber model of tuberculosis: Implications for the treatment of disseminated and meningial tuberculosis in children. *Pediatr Infect Dis J* 39: 1092–1100
- Stammes MA, Bakker J, Vervenne RAW, Zijlmans DGM, van Geest L, Vierboom MPM et al (2021) Recommendations for standardizing thorax pet-ct in non-human primates by recent experience from macaque studies. *Animals* 11:204
- Starck HJ, Viehmann P (1955) Usefulness of syrian gold hamster in diagnosis of tuberculosis. *Zentralbl Bakteriol Orig* 162:446–451
- Steenken W Jr, Pratt PC (1949) Streptomycin in experimental tuberculosis; effect on the pathogenesis of early tuberculosis in the guinea pig infected with streptomycin-sensitive h37 rv tubercle bacilli. *Am Rev Tuberc* 59:664–673
- Steenken W Jr, Wagley PF (1945) Comparison of the golden hamster with the guinea pig following inoculations of virulent tubercle bacilli. *Proc Soc Exp Biol Med* 60:255–257
- Sterling TR, Lin PL (2020) Treatment of latent m. Tuberculosis infection and use of antiretroviral therapy to prevent tuberculosis. *J Clin Invest* 130:5102–5104
- Stockinger DE, Roellich KM, Vogel KW, Eiffert KL, Torrence AE, Prentice JL et al (2011) Primary hepatic mycobacterium tuberculosis complex infection with terminal dissemination in a pig-tailed macaque (*macaca nemestrina*). *J Am Assoc Lab Anim Sci* 50:258–262
- Stringer LA, Wilson PR, Heuer C, Hunnam JC, Mackintosh CG (2011) Effect of vaccination and natural infection with mycobacterium avium subsp. Paratuberculosis on specificity of diagnostic tests for bovine tuberculosis in farmed red deer (*cervus elaphus*). *N Z Vet J* 59:218–224
- Subbian S, Tsenova L, O'Brien P, Yang G, Kushner NL, Parsons S et al (2012) Spontaneous latency in a rabbit model of pulmonary tuberculosis. *Am J Pathol* 181:1711–1724
- Subbian S, Bandyopadhyay N, Tsenova L, O'Brien P, Khetani V, Kushner NL et al (2013a) Early innate immunity determines outcome of mycobacterium tuberculosis pulmonary infection in rabbits. *Cell Commun Signal* 11:60

- Subbian S, O'Brien P, Kushner NL, Yang G, Tsenova L, Peixoto B et al (2013b) Molecular immunologic correlates of spontaneous latency in a rabbit model of pulmonary tuberculosis. *Cell Commun Signal* 11:16
- Sugawara I, Mizuno S (2008) Higher susceptibility of type 1 diabetic rats to mycobacterium tuberculosis infection. *Tohoku J Exp Med* 216:363–370
- Sugawara I, Udagawa T, Yamada H (2004a) Rat neutrophils prevent the development of tuberculosis. *Infect Immun* 72:1804–1806
- Sugawara I, Yamada H, Mizuno S (2004b) Pathological and immunological profiles of rat tuberculosis. *Int J Exp Pathol* 85:125–134
- Sugawara I, Yamada H, Mizuno S (2004c) Pulmonary tuberculosis in spontaneously diabetic goto kakizaki rats. *Tohoku J Exp Med* 204:135–145
- Sugawara I, Yamada H, Mizuno S (2006) Nude rat (f344/n-rnu) tuberculosis. *Cell Microbiol* 8:661–667
- Sugawara I, Yamada H, Mizuno S (2007) Bcg vaccination enhances resistance to m. tuberculosis infection in guinea pigs fed a low casein diet. *Tohoku J Exp Med* 211:259–268
- Sugawara I, Udagawa T, Aoki T, Mizuno S (2009) Establishment of a guinea pig model of latent tuberculosis with gfp-introduced mycobacterium tuberculosis. *Tohoku J Exp Med* 219:257–262
- Sun H, Ma X, Zhang G, Luo Y, Tang K, Lin X et al (2012) Effects of immunomodulators on liquefaction and ulceration in the rabbit skin model of tuberculosis. *Tuberculosis* 92:345–350
- Sun C, Yang G, Yuan J, Peng X, Zhang C, Zhai X et al (2017) Mycobacterium tuberculosis hypoxic response protein 1 (hrp1) augments the pro-inflammatory response and enhances the survival of mycobacterium smegmatis in murine macrophages. *J Med Microbiol* 66:1033–1044
- Swaim LE, Connolly LE, Volkman HE, Humbert O, Born DE, Ramakrishnan L (2006) Mycobacterium marinum infection of adult zebrafish causes caseating granulomatous tuberculosis and is moderated by adaptive immunity. *Infect Immun* 74:6108–6117
- Takaki K, Ramakrishnan L, Basu S (2018) A zebrafish model for ocular tuberculosis. *PLoS One* 13:e0194982
- Tavolara TE, Niazi MKK, Ginese M, Piedra-Mora C, Gatti DM, Beamer G et al (2020) Automatic discovery of clinically interpretable imaging biomarkers for mycobacterium tuberculosis supersusceptibility using deep learning. *EBioMedicine* 62:103094
- Tell LA, Woods L, Foley J, Needham ML, Walker RL (2003) A model of avian mycobacteriosis: clinical and histopathologic findings in japanese quail (*coturnix coturnix japonica*) intravenously inoculated with mycobacterium avium. *Avian Dis* 47:433–443
- Tezera LB, Bielecka MK, Chancellor A, Reichmann MT, Shammari BA, Brace P et al (2017a) Dissection of the host-pathogen interaction in human tuberculosis using a bioengineered 3-dimensional model. *elife* 6:e21283
- Tezera LB, Bielecka MK, Elkington PT (2017b) Bioelectrospray methodology for dissection of the host-pathogen interaction in human tuberculosis. *Bio Protoc* 7:e00312
- Thacker VV, Dhar N, Sharma K, Barrile R, Karalis K, McKinney JD (2020) A lung-on-chip model of early mycobacterium tuberculosis infection reveals an essential role for alveolar epithelial cells in controlling bacterial growth. *elife* 9:e59961
- Thayil SM, Albin TA, Nazari H, Moshfeghi AA, Parel JM, Rao NA et al (2011) Local ischemia and increased expression of vascular endothelial growth factor following ocular dissemination of mycobacterium tuberculosis. *PLoS One* 6:e28383
- Thompson EG, Shankar S, Gideon HP, Braun J, Valvo J, Skinner JA et al (2018) Prospective discrimination of controllers from progressors early after low-dose mycobacterium tuberculosis infection of cynomolgus macaques using blood rna signatures. *J Infect Dis* 217:1318–1322
- Tornack J, Reece ST, Bauer WM, Vogelzang A, Bandermann S, Zedler U et al (2017) Human and mouse hematopoietic stem cells are a depot for dormant mycobacterium tuberculosis. *PLoS One* 12:e0169119
- Trofimov V, Kicka S, Mucaria S, Hanna N, Ramon-Olayo F, Del Peral LV et al (2018) Antimycobacterial drug discovery using mycobacteria-infected amoebae identifies anti-infectives and new molecular targets. *Sci Rep* 8:3939

- Tsenova L, Ellison E, Harbacheuski R, Moreira AL, Kurepina N, Reed MB et al (2005) Virulence of selected mycobacterium tuberculosis clinical isolates in the rabbit model of meningitis is dependent on phenolic glycolipid produced by the bacilli. *J Infect Dis* 192:98–106
- Tsenova L, Harbacheuski R, Sung N, Ellison E, Fallows D, Kaplan G (2007) Bcg vaccination confers poor protection against m. Tuberculosis hn878-induced central nervous system disease. *Vaccine* 25:5126–5132
- Tsenova L, Fallows D, Kolloli A, Singh P, O'Brien P, Kushner N et al (2020) Inoculum size and traits of the infecting clinical strain define the protection level against mycobacterium tuberculosis infection in a rabbit model. *Eur J Immunol* 50:858–872
- Tsujimura Y, Shiogama Y, Soma S, Okamura T, Takano J, Urano E et al (2020) Vaccination with intradermal bacillus calmette-guerin provides robust protection against extrapulmonary tuberculosis but not pulmonary infection in cynomolgus macaques. *J Immunol* 205:3023–3036
- Tucker EW, Pokkali S, Zhang Z, DeMarco VP, Klunk M, Smith ES et al (2016) Microglia activation in a pediatric rabbit model of tuberculous meningitis. *Dis Model Mech* 9:1497–1506
- Tucker EW, Guglieri-Lopez B, Ordonez AA, Ritchie B, Klunk MH, Sharma R et al (2018) Noninvasive (11)c-rifampin positron emission tomography reveals drug biodistribution in tuberculous meningitis. *Sci Transl Med* 10:965
- Turner OC, Basaraba RJ, Orme IM (2003a) Immunopathogenesis of pulmonary granulomas in the guinea pig after infection with mycobacterium tuberculosis. *Infect Immun* 71:864–871
- Turner OC, Keefe RG, Sugawara I, Yamada H, Orme IM (2003b) Swr mice are highly susceptible to pulmonary infection with mycobacterium tuberculosis. *Infect Immun* 71:5266–5272
- Ugaz EM, Pinheiro SR, Guerra JL, Palermo-Neto J (1999) Effects of prenatal diazepam treatment on mycobacterium bovis-induced infection in hamsters. *Immunopharmacology* 41:209–217
- van Leeuwen LM, van der Kuip M, Youssef SA, de Bruin A, Bitter W, van Furth AM et al (2014) Modeling tuberculous meningitis in zebrafish using mycobacterium marinum. *Dis Model Mech* 7:1111–1122
- Van Rhijn I, Godfroid J, Michel A, Rutten V (2008) Bovine tuberculosis as a model for human tuberculosis: advantages over small animal models. *Microbes Infect* 10:711–715
- van Well GT, Wieland CW, Florquin S, Roord JJ, van der Poll T, van Furth AM (2007) A new murine model to study the pathogenesis of tuberculous meningitis. *J Infect Dis* 195:694–697
- van Wijk RC, Hu W, Dijkema SM, van den Berg DJ, Liu J, Bahi R et al (2020) Anti-tuberculosis effect of isoniazid scales accurately from zebrafish to humans. *Br J Pharmacol* 177:5518–5533
- Via LE, Lin PL, Ray SM, Carrillo J, Allen SS, Eum SY et al (2008) Tuberculous granulomas are hypoxic in guinea pigs, rabbits, and nonhuman primates. *Infect Immun* 76:2333–2340
- Via LE, Schimel D, Weiner DM, Dartois V, Dayao E, Cai Y et al (2012) Infection dynamics and response to chemotherapy in a rabbit model of tuberculosis using [(1)(8)f]2-fluoro-deoxy-d-glucose positron emission tomography and computed tomography. *Antimicrob Agents Chemother* 56:4391–4402
- Via LE, Weiner DM, Schimel D, Lin PL, Dayao E, Tankersley SL et al (2013) Differential virulence and disease progression following mycobacterium tuberculosis complex infection of the common marmoset (*callithrix jacchus*). *Infect Immun* 81:2909–2919
- Viallier J, Cayre RM (1955) Behavior of the golden hamster inoculated with bcg vaccine and with strains of homologous tubercle bacilli. *C R Seances Soc Biol Fil* 149:1991–1993
- Wachtman LM, Miller AD, Xia D, Curran EH, Mansfield KG (2011) Colonization with nontuberculous mycobacteria is associated with positive tuberculin skin test reactions in the common marmoset (*callithrix jacchus*). *Comp Med* 61:278–284
- Walsh GP, Tan EV, dela Cruz EC, Abalos RM, Villahermosa LG, Young LJ et al (1996) The philippine cynomolgus monkey (*macaca fascicularis*) provides a new nonhuman primate model of tuberculosis that resembles human disease. *Nat Med* 2:430–436
- Walter FR, Gilpin TE, Herbath M, Deli MA, Sandor M, Fabry Z (2020) A novel in vitro mouse model to study mycobacterium tuberculosis dissemination across brain vessels: A combination granuloma and blood-brain barrier mouse model. *Curr Protoc Immunol* 130:e101

- Wang C, Zhang Q, Tang X, An Y, Li S, Xu H et al (2019) Effects of cwlM on autolysis and biofilm formation in *Mycobacterium tuberculosis* and *Mycobacterium smegmatis*. *Int J Med Microbiol* 309:73–83
- Wasz-Hockert O, Backman A (1954) Effect of various vaccines on the course of experimental guinea pig tuberculosis. *Ann Paediatr Fenn* 1:91–98
- Waters WR, Palmer MV, Olsen SC, Sacco RE, Whipple DL (2003) Immune responses of elk to *Mycobacterium bovis* bacillus Calmette-Guérin vaccination. *Vaccine* 21:1518–1526
- Waters WR, Maggioli MF, McGill JL, Lyashchenko KP, Palmer MV (2014) Relevance of bovine tuberculosis research to the understanding of human disease: historical perspectives, approaches, and immunologic mechanisms. *Vet Immunol Immunopathol* 159:113–132
- Wayne LG (2001) In vitro model of hypoxically induced nonreplicating persistence of *Mycobacterium tuberculosis*. *Methods Mol Med* 54:247–269
- Wayne LG, Hayes LG (1996) An in vitro model for sequential study of shutdown of *Mycobacterium tuberculosis* through two stages of nonreplicating persistence. *Infect Immun* 64:2062–2069
- Webb EK, Saccardo CC, Poling A, Cox C, Fast CD (2020) Rapidly training African giant pouched rats (*Cricetomys ansorgei*) with multiple targets for scent detection. *Behav Process* 174:104085
- Weikert LF, Lopez JP, Abdolrasulnia R, Chronos ZC, Shepherd VL (2000) Surfactant protein A enhances mycobacterial killing by rat macrophages through a nitric oxide-dependent pathway. *Am J Physiol Lung Cell Mol Physiol* 279:L216–L223
- Wessler T, Joslyn LR, Borish HJ, Gideon HP, Flynn JL, Kirschner DE et al (2020) A computational model tracks whole-lung *Mycobacterium tuberculosis* infection and predicts factors that inhibit dissemination. *PLoS Comput Biol* 16:e1007280
- West CS, Vainisi SJ, Vygantas CM, Beluhan FZ (1981) Intraocular granulomas associated with tuberculosis in primates. *J Am Vet Med Assoc* 179:1240–1244
- Whelan AO, Coad M, Cockle PJ, Hewinson G, Vordermeier M, Gordon SV (2010) Revisiting host preference in the *Mycobacterium tuberculosis* complex: experimental infection shows *M. tuberculosis* H37Rv to be avirulent in cattle. *PLoS One* 5:e8527
- Wilkinson PC, White RG (1966) The role of mycobacteria and silica in the immunological response of the guinea-pig. *Immunology* 11:229–241
- Williams A, Hatch GJ, Clark SO, Gooch KE, Hatch KA, Hall GA et al (2005) Evaluation of vaccines in the EU TB vaccine cluster using a guinea pig aerosol infection model of tuberculosis. *Tuberculosis* 85:29–38
- Williams WR, Trout J, Creissen E, Bielefeldt-Ohmann H, Johnston MS, Kendall LV et al (2020) Evaluation of peripheral blood markers as early endpoint criteria in guinea pigs (*Cavia porcellus*) when testing tuberculosis vaccine candidates. *Comp Med* 70:45–55
- Winchell CG, Mishra BB, Phuah JY, Saqib M, Nelson SJ, Maiello P et al (2020) Evaluation of IL-1 blockade as an adjunct to linezolid therapy for tuberculosis in mice and macaques. *Front Immunol* 11:891
- Wolf RH, Bullock BC, Clarkson TB (1967) Tuberculosis in the stump-tailed macaque (*Macaca speciosa*). *J Am Vet Med Assoc* 151:914–917
- Wolf TM, Sreevatsan S, Singer RS, Lipende I, Collins A, Gillespie TR et al (2016) Noninvasive tuberculosis screening in free-living primate populations in Gombe National Park, Tanzania. *EcoHealth* 13:139–144
- Xu J, Tasneen R, Peloquin CA, Almeida DV, Li SY, Barnes-Boyle K et al (2018) Verapamil increases the bioavailability and efficacy of bedaquiline but not clofazimine in a murine model of tuberculosis. *Antimicrob Agents Chemother* 62:e01692
- Yagi A, Uchida R, Hamamoto H, Sekimizu K, Kimura KI, Tomoda H (2017) Anti-mycobacterium activity of microbial peptides in a silkworm infection model with *Mycobacterium smegmatis*. *J Antibiot* 70:685–690
- Yagi A, Yamazaki H, Terahara T, Yang T, Hamamoto H, Imada C et al (2021) Development of an in vivo-mimic silkworm infection model with *Mycobacterium avium* complex. *Drug Discov Ther* 14:287–295

- Yang G, Luo T, Sun C, Yuan J, Peng X, Zhang C et al (2017) Ppe27 in mycobacterium smegmatis enhances mycobacterial survival and manipulates cytokine secretion in mouse macrophages. *J Interf Cytokine Res* 37:421–431
- Youmans GP, Mc CJ (1945) Streptomycin in experimental tuberculosis; its effect on tuberculous infections in mice produced by *m. Tuberculosis var. Hominis*. *Am Rev Tuberc* 52:432–439
- Youmans GP, Williston EH (1946) Effect of streptomycin on experimental infections produced in mice with streptomycin resistant strains of *m. Tuberculosis var. Hominis*. *Proc Soc Exp Biol Med* 63:131–134
- Yuan T, Sampson NS (2018) Hit generation in tb drug discovery: from genome to granuloma. *Chem Rev* 118:1887–1916
- Zelmer A, Carroll P, Andreu N, Hagens K, Mahlo J, Redinger N et al (2012) A new in vivo model to test anti-tuberculosis drugs using fluorescence imaging. *J Antimicrob Chemother* 67:1948–1960
- Zhan L, Tang J, Sun M, Qin C (2017) Animal models for tuberculosis in translational and precision medicine. *Front Microbiol* 8:717
- Zhang G, Zhu B, Shi W, Wang M, Da Z, Zhang Y (2010) Evaluation of mycobacterial virulence using rabbit skin liquefaction model. *Virulence* 1:156–163
- Zhang T, Li SY, Nuermberger EL (2012) Autoluminescent mycobacterium tuberculosis for rapid, real-time, non-invasive assessment of drug and vaccine efficacy. *PLoS One* 7:e29774
- Zhang X, Mardinoglu A, Joosten LAB, Kuivenhoven JA, Li Y, Netea MG et al (2018) Identification of discriminating metabolic pathways and metabolites in human pbmcs stimulated by various pathogenic agents. *Front Physiol* 9:139
- Zhang N, Strydom N, Tyagi S, Soni H, Tasneen R, Nuermberger EL et al (2020) Mechanistic modeling of mycobacterium tuberculosis infection in murine models for drug and vaccine efficacy studies. *Antimicrob Agents Chemother* 64:e01727